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Abstract
One of the biggest hurdles in clinical therapy is ensuring that drugs have appropriate pharmacokinetic
profiles; they must traffic to sites of interest and accumulate there at relevant concentrations, but must
also be eliminated from tissues at a desirable rate. This is especially important in oncology because
precise tumor locations may be unknown and therapeutics are often toxic to off-target healthy tissues.
Nanoscale drug formulations provide a useful way to modulate and improve the behavior of drugs within
biological systems. For example, gold nanoparticles (AuNPs) can be designed with physiochemical
properties that allow them to traffic from the bloodstream into tumors. Once there, gold can be utilized for
a number of clinical applications in imaging (e.g., photoacoustic, CT) and therapy (e.g., photothermal,
radiosensitization). Gold nanoformulations can also provide an excellent platform for delivery of other
drugs, thereby allowing targeted multifunctional therapy. However, despite their potential utility, gold
particles have been slow to translate into the clinic. One area of concern is the slow biodegradation of
gold; AuNPs that are too large for renal excretion (> 5-10 nm) are likely to persist in tissues for months,
with unknown long-term health consequences. To address this issue, we have developed novel
nanomaterials comprising ultrasmall gold particles (~2-3 nm) that are incorporated within a larger micelle
structure (~50-200 nm). The large overall size promotes localization into tumors; however, the use of
small individual AuNPs improves long-term excretion. In this work, we first present a polymeric micelle
containing ultrasmall AuNPs with a pH-sensitive coating. These nanoassemblies are stable at neutral pH
but dissociate in acidic environments (pH 5.0); they demonstrate rapid degradation within cellular
lysosomes, which contribute to their progressive and substantial in vivo bioelimination. Next, we describe
a multifunctional nanocluster combining ultrasmall AuNPs with a near-infrared dye, indocyanine green,
without the need for additional complexing reagents. In an aggressive mouse breast cancer model,
intravenously-injected clusters accumulate within tumors and enable photoacoustic imaging and
photothermal ablation, ultimately resulting in significantly improved animal survival. Together, these novel
clusters present exciting and useful tools for cancer imaging and therapy.

Degree Type
Dissertation

Degree Name
Doctor of Philosophy (PhD)

Graduate Group
Biochemistry & Molecular Biophysics

First Advisor
Andrew . Tsourkas

Keywords
Biodistribution, Cancer, Gold Nanoparticles, Pharmacokinetics, Photoacoustic Imaging, Photothermal
Therapy

Subject Categories
Nanoscience and Nanotechnology | Pharmacology
This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/3551

ENGINEERING NOVEL NANOMATERIALS FROM ULTRASMALL GOLD CLUSTERS FOR USE
IN CANCER THERAPY
Elizabeth Higbee-Dempsey
A DISSERTATION
in
Biochemistry and Molecular Biophysics
Presented to the Faculties of the University of Pennsylvania
in
Partial Fulfillment of the Requirements for the
Degree of Doctor of Philosophy
2019

Supervisor of Dissertation

Graduate Group Chairperson

_________________________

_________________________

Andrew Tsourkas, Ph.D.

Kim Sharp, Ph.D.

Professor of Bioengingeering

Professor of Biochemistry and Biophysics

Dissertation Committee
Sergei Vinogradov, Ph.D., Professor of Biochemistry and Biophysics
David Chenoweth, Ph.D., Associate Professor of Chemistry
David Cormode, Ph.D., Associate Professor of Radiology
Zhiliang Cheng, Ph.D., Research Associate Professor of Bioengineering

ABSTRACT

ENGINEERING NOVEL NANOMATERIALS FROM ULTRASMALL GOLD CLUSTERS FOR USE
IN CANCER THERAPY
Elizabeth Marie Higbee-Dempsey
Andrew Tsourkas

One of the biggest hurdles in clinical therapy is ensuring that drugs have appropriate
pharmacokinetic profiles; they must traffic to sites of interest and accumulate there at relevant
concentrations, but must also be eliminated from tissues at a desirable rate. This is especially
important in oncology because precise tumor locations may be unknown and therapeutics are
often toxic to off-target healthy tissues. Nanoscale drug formulations provide a useful way to
modulate and improve the behavior of drugs within biological systems. For example, gold
nanoparticles (AuNPs) can be designed with physiochemical properties that allow them to traffic
from the bloodstream into tumors. Once there, gold can be utilized for a number of clinical
applications in imaging (e.g., photoacoustic, CT) and therapy (e.g., photothermal,
radiosensitization). Gold nanoformulations can also provide an excellent platform for delivery of
other drugs, thereby allowing targeted multifunctional therapy. However, despite their potential
utility, gold particles have been slow to translate into the clinic. One area of concern is the slow
biodegradation of gold; AuNPs that are too large for renal excretion (> 5-10 nm) are likely to
persist in tissues for months, with unknown long-term health consequences. To address this
issue, we have developed novel nanomaterials comprising ultrasmall gold particles (~2-3 nm) that
are incorporated within a larger micelle structure (~50-200 nm). The large overall size promotes
localization into tumors; however, the use of small individual AuNPs improves long-term
excretion. In this work, we first present a polymeric micelle containing ultrasmall AuNPs with a
pH-sensitive coating. These nanoassemblies are stable at neutral pH but dissociate in acidic
environments (pH 5.0); they demonstrate rapid degradation within cellular lysosomes, which
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contribute to their progressive and substantial in vivo bioelimination. Next, we describe a
multifunctional nanocluster combining ultrasmall AuNPs with a near-infrared dye, indocyanine
green, without the need for additional complexing reagents. In an aggressive mouse breast
cancer model, intravenously-injected clusters could accumulate within tumors and enable
photoacoustic imaging and photothermal ablation, ultimately resulting in significantly improved
animal survival. Together, these novel clusters present exciting and useful tools for cancer
imaging and therapy.
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CHAPTER 1: INTRODUCTION TO GOLD NANOPARTICLES IN BIOLOGICAL
SYSTEMS

1.1 Overview of nanoparticles
Introduction to nanomaterials
Nanoparticles are discrete units of matter that behave as a single entity
(“particles”) and possess dimensions in the scale of 1 to 1000 nm (“nano”).
Nanoparticles demonstrate unique attributes as a material. Like molecules, their small
size confers high mobility and high specific surface area [1]; however, like bulk materials,
they can possess useful ensemble features [2] including mechanical,[3] magnetic[4],
optical,[5] electric, and thermal properties. As a result, nanomaterials have been
increasingly explored in both the physical and life sciences. In biological systems, they
show great promise for the diagnosis, treatment, and prevention of disease.
Nanomaterials can be broadly classified by a number of intersecting categories,
the most common of which are based on component materials (organic vs. inorganic,
biologically-derived material vs. synthetic). Other important distinctions include shape
(spherical vs. nonspherical); preparation route (chemical vs. physical/mechanical vs.
biological, bottom-up vs. top-down); and a range of morphological features (size,
structure) and functional applications. [6–8]
Gold nanoparticles
Gold nanoparticles (AuNPs) are among the oldest-known and best-studied
nanoformulations.[9] Gold is a highly useful material with unique physiochemical
properties: high atomic number, surface plasmon resonance, redox behavior,
1

conductivity, optoelectronic properties, etc.[10,11] AuNPs can be synthesized in a wide
range of sizes (from smaller than 1 nm to larger than 500 nm), as well as a range of
shapes (including spheres, rods, stars, triangles, boxes, shells, and cages), and under
mild reaction conditions (typically atmospheric oxygen and moderate temperatures).
Gold surfaces can also be easily functionalized with self-assembled monolayers of
thiols, due to the favorable bond formed between gold and sulfur. [12–14] By this method, a
wide range of thiolate materials have been used to coat AuNP surfaces, including:
alkanes, polymers, antibodies and other proteins, and oligonucleotides.[11]
1.2 Gold nanoparticle formulations
Synthesis of gold cores
The classical method of AuNP synthesis was described in 1951 by Turkevich et
al.[15] In this method, tetrachloroauric acid is reduced by trisodium citrate in boiling
water, yielding gold spheres with hydrophilic citrate-stabilized surfaces. This original
protocol produced 15-20 nm gold spheres; a later breakthrough by Frens et al in 1973
determined that the gold-to-citrate ratio could be manipulated in order to generate a
range of particle sizes, from 16 to 147 nm. [16] Other refinements have included the use
of alternate reducing agents (e.g. ascorbate, UV irradiation) that improve the spherical
definition of particles.[17]
In 1994, Brust and Schriffin reported a landmark strategy for producing
hydrophobic gold spheres.[18] In a two-phase system, using tetraoctylammonium
bromide as a phase transfer reagent, gold salt is reduced by sodium borohydride and
coated with alkanethiols. Particles produced by this method have the advantage of
ultrasmall size (approximately 1-5 nm), as well as high stability conferred by the ligand
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coating; these thiols form a monolayer that strongly associates with the gold surface
through Au-S bonds and with neighbor thiols through van der Waals interactions. [13,19]
Many other innovative syntheses have been reported that greatly expand the
repertoire of gold nanoparticles. Some examples include: using ammonium surfactants
to form gold nanorods, which have unique resonant properties and biological
interactions;[20–22] the formation of gold nanoshells, which exhibit tunable optical
properties based on their size;[23–25] and the creation of ultrasmall (< 2 nm) gold
nanoparticles, including those with known atomic structure and molecule-like properties
such as photoluminescence.[26,27]
Conjugation and surface coating
The surface composition of AuNPs can be tailored by using one or several
general strategies (Figure 1.1).

Figure 1.1. Modulation of gold surfaces can follow several different schemes. Adapted by permission from
Love et al.[13]

As noted, gold particles complex with surface ligands during their formation;
these may be weakly-associated stabilizing agents like citrate, phosphines, and
3

amines[28–30] or strongly-bound thiols. Many AuNP formulations have been developed
with the specific goal of incorporating desired ligands during initial synthesis, often using
biologically relevant molecules: glutathione,[31,32] coenzyme A,[33] tiopronin (a
pharmaceutical),[33] ethylene glycols,[34–36] and others.[13]
If the desired ligand cannot be directly incorporated, it can sometimes be
generated by chemical modification of surface ligands. A very common reaction
technique is through peptide coupling.[37–39] Classic organic mechanisms can also be
employed, such as alkene metathesis, [40] nucleophilic substitutions,[41] and click
chemistry.[42,43]
Alternatively, an existing surface ligand may be displaced by a new ligand. This
approach is used to confer long-term stability on citrate AuNPs and other non-thiolated
gold particles. Exchange can occur rapidly through simple mixing, though occasionally
an intermediary ligand is introduced (e.g., Tween 20, lipoic acid) to minimize potential
aggregation of particles).[44,45] Another intermediary ligand, 4‐dimethylaminopyridine
(DMAP), has been used to transition particles from hydrophobic to hydrophilic in a fourstage process: 1) particles are synthesized by the Brust method in the absence of
alkanethiols; 2) the resulting amine-stabilized particles undergo ligand exchange with
DMAP; 3) DMAP acquires a positive charge and confers water solubility on the particle;
and 4) particles can then undergo additional ligand exchange reactions with hydrophilic
thiols in aqueous media.[29] Ligand exchange can also occur on particles that are
already coated with thiolates. This exchange occurs by associative substitution – that is,
an incoming thiol (or disulfide) displaces a bound thiolate by way of a short-lived
intermediate complex, similar to nucleophilic attack reaction/mechanisms.[41,46–48] By
equilibrating thiolated particles with an excess of the desired thiol (typically a 10-fold
4

molar excess), near- to complete-exchange can occur. This method can also be used to
decorate particle surfaces with a heterogeneous mix of materials.
Larger assemblies
Gold particles have also been incorporated into a variety of large, complex
structures, often involving noncovalent interactions such as electrostatic and proteinsubstrate (e.g., avidin-biotin).[49,50] One common noncovalent method is to encapsulate
hydrophobic AuNPs using amphiphilic materials that thereby confer water solubility
without chemical modification. Amphiphilic materials can be natural or synthetic (e.g.,
lipids, polymers, proteins, small molecules). Based on their properties, and especially
their amphiphilic mass ratio, they can form a variety of structures. Common examples of
structures include micelles (monolayer of amphiphiles) and vesicles like liposomes and
polymersomes (bilayer of amphiphiles). As an advantage, these macrostructures allow
the incorporation of multifunctional materials within a single moiety, without the need for
complex synthetic conjugation strategies; this has been demonstrated to great effect as
a strategy to co-encapsulate therapeutic compounds, allowing delivery of multiple
synergistic pharmaceuticals or allowing concomitant imaging and treatment of
disease.[51]
1.3 Nanoparticle behavior in biological systems
Introduction to nano-bio interactions
Nanoparticles, including AuNPs, exhibit unique behavior within biological
systems. This behavior is often critical to their clinical utility over other materials, and yet
it can be difficult to fully understand and control these complex interactions. To achieve
their full efficacy, it is often necessary for particles to reach specific tissues, cell types, or
5

even subcellular compartments, while avoiding off-target locations. There must also be
control over dosage and kinetics, as well as considerations of their eventual degradation
and/or elimination. Evaluations of nano-bio interactions must include both an accounting
of the particle’s physiochemical properties – size, shape, composition, etc. – as well as
understanding of the biological environments on molecular, cellular, and organismal
scales.
1.3.1 Molecular interactions
When nanoparticles enter physiological environments, such as after intravenous
injection, they interact with proteins that non-specifically adsorb to their outer surface
due to high surface free energy.[52,53] This protein corona forms rapidly[54] and consists of
two temporal and spatial phases. Initially, the nanoparticle will be surrounded by a “soft”
corona wherein the highest-abundance proteins associate dynamically with the particle
surface; after longer exposure, the innermost layer of proteins will be displaced by those
with the highest binding affinity, and this “hard” corona may be irreversibly bound to the
particle surface.[55,56] It has been proposed that the protein corona is what the cell truly
“sees”, and therefore studies of the nano-bio interface should consider it as equally or
more important than the particle’s bare surface composition. [57]
The composition of the protein corona is greatly influenced by the
physiochemical makeup of the nanoparticle.[55] Because such a large number of
parameters contribute to these interactions, it is often highly difficult to assess their
relative contributions; still, some general trends have been reported. For example, a
number of studies[58–61] – including several landmark proteomics studies reported by
Tenzer et al[54,62] – have demonstrated that protein identity and relative abundance vary
with particle size and surface charge. Corona proteins can also undergo conformational
6

changes, particularly upon association with hydrophobic particles, [63] positively-charged
particles,[64] strongly-negatively-charged particles,[65] and rod-shaped particles.[66]
Greater quantities of adsorbed proteins (i.e., thicker coronas) have been seen on larger
particles[60], hydrophobic particles[67], particles with rough surfaces,[68] and on rod-shaped
particles compared to spheres.[69] Biological contributions are also highly important,
even within a single medium such as serum. For example, the identities of adsorbed
corona proteins can change based on serum concentrations (such as those used for
typical in vitro experiments vs. in vivo),[70] and differences very likely occur between
species, disease states, and individuals. Furthermore, variations in the protein corona
are likely to have a direct impact on interactions between nanoparticles and cells,
including pharmacokinetics, toxicity, and cell selectivity.[54]
1.3.2 Cellular interactions
Particle properties greatly affect interactions with cells, both through coronal
variations and more generally. For example, positively charged nanoparticles tend to
have faster cellular uptake and higher cytotoxic potential, even after complexing with
serum proteins.[65] The enormous impact of surface charge typically arises from the
interaction between particles and the phospholipid head groups and protein domains
found on the cell membrane; generally, positive nanoparticles have greater associations
with the largely negative lipids found on the cell surface, though the impact of this on cell
uptake varies between cell lines.[71] Other cell surface elements can contribute to this
interplay, including glycans (which may act as a barrier) and specific membrane
proteins.
Endocytosis
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Nanoparticles typically enter cells through endocytosis.[72–74] In this process,
extracellular material is enveloped by cellular membrane; these cavities then pinch off
from the outer plasma membrane to form intracellular vesicles that are broadly known as
endosomes (Figure 1.2). Endosomes transport material throughout the cell and into
other specialized vesicular compartments, including other endosomes. A range of
different types of endosomes are defined by their unique protein markers and distinct
functions. A common target for nanoparticles and other materials is the so-called early
endosome.[72,73]

Figure 1.2. Mechanisms of endocytosis and intracellular vesicle trafficking. Reproduced by permission
from Springer Nature Customer Service Centre GmbH: Springer Nature, Nature Reviews Molecular Cell
Biology, Mayor and Pagano, 2007.[75]

Phagocytosis
Phagocytosis, or cellular “eating”, is typically performed by specialized cell types,
termed professional phagocytes, which include macrophages, neutrophils, monocytes,
dendritic cells, and mast cells. These cells are responsible for engulfing large cargo
8

(e.g., pathogenic organisms, cellular debris, and aged cells), performing a critical role in
immunity and tissue homeostasis. Phagocytosis can also be performed
“nonprofessionally” by several other cell types, including fibroblasts, epithelial cells, and
endothelial cells. Their phagocytic functions tend to be more restricted, such as in time
(e.g., during development) or by target (e.g., apoptotic bodies only). [76–78]
Cargo is tagged for phagocytosis through affiliation with phagocyte surface
receptors. This molecular recognition may occur either by direct recognition of cargo
features or through intermediary proteins bound to cargo surface. These latter proteins,
known as collectively as opsonins, include proteins from adaptive immunity
(immunoglobulins) and innate immunity (complement proteins) as well as other
circulating proteins.[79,80] Binding of cargo to the phagocyte surface triggers activation of
cytoskeletal actin and extension of cellular pseudopodia, which envelop particles and
form phagosomes.[78]
Pinocytosis
Many other forms of endocytic uptake can be classified as pinocytosis, or cellular
“drinking”. Unlike phagocytosis, these processes are performed by many eukaryotic cell
types. In the process known as macropinocytosis,[81,82] actin-driven pseudopodia extend
outward from the cell and then fold back towards the cell surface, engulfing pockets of
extracellular fluids and their contents. Adsorptive pinocytosis, sometimes called fluidphase endocytosis, involves the uptake of molecules that interact with the membrane
through nonspecific hydrophobic and/or electrostatic interactions. After internalization of
these vesicles, intracellular trafficking tends to be relatively slow compared to higheraffinity, receptor mediated endocytosis.[83]
9

Specific macromolecular cargo can be recognized by specialized cell surface
receptors and internalized through receptor-mediated endocytosis. One such pathway
uses proteins called clathrins that line the interior of the plasma membrane in localized
receptor-rich regions and induce inward curvature.[84] In mammalian cells, clathrin
endocytosis is responsible for the uptake of key moieties including cholesterol (via lowdensity lipoprotein)[85] and transferrin.[86] Although clathrin endocytosis is the canonical
pathway of receptor-mediated uptake, clathrin has also been implicated in fluid phase
endocytosis.
Another common receptor-mediated pathway involves membrane invaginations
called caveolae; these are formed from associations of caveolin and cavin proteins with
highly hydrophobic, cholesterol-enriched membrane domains.[87,88] After membrane
scission, budded caveolae may fuse with early endosomes or with specialized
compartments called caveosomes;[89] these vesicles are distinct from early endosomes
in that they are pH neutral and they can bypass the early endosome’s downstream cargo
degradation pathways.[90] Caveolae have also been implicated in transcytotic trafficking
across polarized cells including vascular endothelial cells,[91,92] though other data is
mixed.[93,94] Both clathrin- and caveolae-mediated endocytosis canonically utilize the
GTPase dynamin for scission of vesicles from the plasma membrane [95–97].
Several other receptor-mediated pathways have been reported that utilize neither
clathrin nor caveolae. Though characterization of their mechanisms and specificity is
underdeveloped, several of these pathways are identified by their association with
particular small GTPases.[75,98] The RhoA-regulated pathway, which also employs
dynamin for scission, has been implicated in the uptake of interleukin-2 and several
other cytokines. The Cdc42-regulated and ARF6-regulated pathways differ from the
10

other receptor-mediated pathways described in that they do not use dynamin, and they
traffic to distinct types of endosomes – GPI-AP-enriched early endosomal compartments
(GEECs)[99,100] or tubular recycling endosomes,[101,102] respectively.
Nanoparticle internalization
All of the described endocytic mechanisms have been associated with
nanoparticle uptake, though certain forms predominate. As with the formation of the
protein corona, cellular interactions with nanoparticles can vary greatly depending on
nanoparticle form and composition. Indeed, the protein corona itself can strongly
mediate these interactions, since a number of endocytic mechanisms involve binding
specific proteins (e.g., immunoglobulins for phagocytosis, albumin for receptor-mediated
endocytosis). Multiple contributions may also be difficult to deconvolute, and can even
seem contradictory; for example, large elongated particles may have stronger
membrane interactions through higher binding valency, but also require more membrane
deformation for internalization.[103] Variations that seem minor can have a large impact;
for example, one study found that increasing particle diameter from 100 nm to 200 nm
could switch uptake from clathrin- to caveole-mediated mechanisms.[104]
A commonly discussed phenomenon is the discrepancy of nanoparticle size with
receptor-mediated endocytosis. A single flask-shaped caveolae has a diameter of 60-80
nm, and the typical size of a clathrin-coated pit is 60-120 nm.[84,90] However, a number of
studies have demonstrated strong evidence for these pathways’ involvement in uptake
of very large nanoparticles. Notably, several bacterial strains appear to use these
pathways, despite their micrometer size.[105]
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Nanoparticles may be directed towards a specific cell type or cell internalization
mechanism through active targeting. For example, placement of folate on particle
surfaces has been used to accumulate nanomaterials in cancer cells overexpressing
folate receptor, and encourage particle internalization through caveolae.[106,107]
Abraxane®, one of the earliest-approved and most successful nanomaterials, contains
albumin that is designed to promote transcytosis across the vascular wall via caveolaemediated mechanisms.[108,109]
Endosomal trafficking
As mentioned, the destination for many pinocytic vesicles is early endosomes,
where the engulfed material is separated and sorted. [72,73] For example, membrane
receptors can be dissociated from their bound cargo due to the endosome’s acidic
internal environment (pH 6.0 to 6.2), which is maintained by resident V-ATPase proton
pumps.[110,111] The majority of membrane proteins are recycled back to the outer
membrane. Material destined for degradation is then packaged into trafficking vesicles,
transported along microtubules towards the cell center, and fused with late endosomes.
Late endosomes are more acidic (pH 5.5 to 6.0) and contain hydrolytic enzymes; these
vesicles fuse with and mature into lysosomes, which have increased acidity (pH 4.5 to
5.0) and a large cohort of lytic enzymes.[112]
Phagosomes undergo a similar maturation process involving progressive
acidification and changes in enzymatic content. [78,113] Phagosomes have fusion events
with early endosomes, transitioning into late phagosomes while moving along
microtubules towards the cell center. Finally, late phagosomes fuse with lysosomes to
form phagolysosomes.[113] Phagolysosome composition can vary significantly between
different phagocyte types. For example, they are highly acidic (as low as pH 4.5) in M2
12

macrophages, which are primarily responsible for clearing apoptotic and necrotic
material. However, phagocytes involved with elimination of pathogens, such as M1
macrophages and neutrophils, undergo a slower rate and/or lower extent of acidification;
this has been attributed to a number of mechanisms[114,115] including delayed fusion with
lysosomes, fewer copies of V-ATPase, leakage of protons through increased
phagosome membrane permeability, and consumption of protons by superoxide. In
these cells, reduced lysosomal acidity is associated with greater production of reactive
oxygen species (through the activity of NADPH oxidase) and highly effective
antimicrobial activity.[113,115]
Notably, some endocytic vesicles (e.g., caveosomes) – can bypass these
pathways; this phenomenon is exploited by a number of pathogens,[89,90,105,116,117] and
could be used as a mechanism for delivering therapeutics while avoiding their lysosomal
degradation.[109,118]
Cytosolic entry
For many important therapeutic targets, nanoparticles (and other drugs) must
reach the cytoplasm. The advantages of this include: delivery of cytosolically active
agents, such as proteins and nucleic acids; ability to interact with native cytosolic
structures, such as organelles; and avoidance of negative endosomal/lysosomal effects,
including quenching of imaging agents[119–121] and degradation of materials. In order to
access the cytosol, particles have been designed to traverse the lipid membrane using
several strategies.
Particles that are very small (1-4 nm) – or, very small in at least one dimension –
may be capable of directly penetrating the plasma membrane. [122,123] To deliver larger
13

particles, a common strategy is coating particle surfaces with cell penetrating peptides;
as their name suggests, these short (5-30 amino acids) and typically net-cationic
peptides are capable of passing through cell membranes, often without overt membrane
disruption.[124–126] This method has been used to deliver gold nanoparticles [127] and a
variety of other nanomaterials like iron oxide nanoparticles,[128] liposomes,[129–132] and
polyplexes.[133] Particle surfaces can also be designed to mimic physiochemical features
of cell penetrating peptides, such as an ordered arrangement of hydrophobic and ionic
groups.[134]
Other techniques for cytosolic delivery involve escape from intracellular
endosomes. One such strategy, dubbed the “proton sponge” method, [135–137] involves
loading endosomes with nanomaterials that possess high proton buffering capacity
(usually titratable polyamines). As these materials sequester endosomal protons, they
can swell due to intramolecular electrostatic repulsion; at the same time, the continued
activity of V-ATPase pumps will result in progressive accumulation of 1) chloride ions,
which passively influx to balance transmembrane voltage, and 2) water, due to the
resulting osmotic pressure. These two forces cause endosomes to rupture, allowing
leakage of nanoparticle cargo into the cytosol. [136,138] Another endosomal escape
strategy employs a different class of peptides known as membrane-destabilizing
peptides or endosome-disrupting peptides. These peptides, many of which are derived
from viral proteins, trigger membrane disruption in response to endosomal
environmental cues such as low pH,[139,137] allowing escape of associated nanoparticles
and other cargo.[140,141] Importantly, methods of cytosolic entry may result in cytotoxicity
due to disruption of the outer membrane (hole formation and/or membrane thinning).[142]
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1.3.3 Organismal interactions
The majority of nanomedicines are designed to be injected as a bolus into
peripheral veins.[143] Their initial interactions within the bloodstream will therefore include
the vascular endothelial cells that line vessel walls, but will also include circulating cells
(erythrocytes, leukocytes, and platelets) and circulating proteins (albumin, globulins,
fibrinogens, and regulatory proteins). [60,144,145] Particles may also be marginated to
different areas of the vessel cross section (i.e., towards the outer walls) due to fluid
tumbling dynamics and interactions with other circulating materials. [146] As particles are
carried to the heart, they will first encounter capillary beds within the lungs; this may
cause very large particles to become deposited there. Other/smaller particles will enter
the arterial system and move into organs (Figure 1.3).

Figure 1.3. Potential trends in nanoparticle distribution based on size, shape, and surface charge.
Reproduced by permission from Springer Nature Customer Service Centre GmbH: Springer Nature, Nature
Biotechnology, Blanco et al, 2015.[147]

Healthy vasculature
Much of the body’s vasculature consists of continuous endothelium, with
nonfenestrated endothelial cells connected via tight junctions and adherens junctions. [148]
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Due to their size, most nanomaterials are unable to pass between these cells, so can
only exit these vessels and enter tissues by endocytic uptake through cells, i.e.
transcytosis. However, within some tissues, endothelial cells contain small constitutive
holes called fenestrae.[148] In organs such as the kidney, these openings (approximately
60-80 nm) are effectively narrowed to 5-6 nm by filamentous diaphragms; by contrast,
the liver and spleen contain larger sinusoidal gaps (approximately 100-250 nm), no
diaphragms, and a discontinuous basement membrane. [144,148,149] As blood passes
through these vessels, nanoparticles can leak out of pores and accumulate within these
organs in a matter of minutes, being effectively filtered by size. [143,147]
Organs compartments
Once particles leave fenestrated vessels and enter an organ, they must perfuse
through the extracellular microenvironment and its assortment of matrix proteins and
glycans (e.g., laminin, collagen) which have the potential to impede diffusion of
nanoparticles.[146,150,151] In the liver and spleen, particles will encounter large populations
of resident tissue macrophages that comprise the mononuclear phagocyte system
(MPS, formerly known as the reticuloendothelial system, RES). [152,153] These tissue
macrophages are often the dominant consumers of intravenously-administered
nanoparticles.
Spleen
The spleen plays a major role in filtration and elimination of pathogenic
organisms and aged erythrocytes; nanomaterials can be similarly scavenged due to
shared characteristics (i.e., nano size, opsonization, and low deformability).[146,154,155]
Studies in rodents have found that smaller nanoparticles (15-200 nm) tend to be taken
up by a subset of macrophages found in the spleen’s marginal zone (the junction
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between red and white pulps),[156,157] while larger particles end up in red pulp
macrophages.[158] Notably, human spleens have different architecture (e.g., no marginal
zone and different macrophage subtypes), so studies performed in rodents and other
animals may not accurately reflect nanoparticle behavior in humans.[159,160]

Liver
Like the spleen, the liver sequesters pathogens and aged red blood cells; it also
has a special role in elimination of large lipoprotein particles (> 200 nm) called
chylomicrons.[144,148,161] The liver’s resident macrophages, termed Kupffer cells, form the
body’s largest reservoir of tissue macrophages (often reported as 50-80%).[162,163] These
cells commonly internalize large fractions of nanoparticles, particularly opsonized
particles. Notably, particles can also be taken up by hepatic sinusoidal epithelial cells,
which tend to have high endocytic activity; it has been proposed that these are a major
source of receptor-mediated endocytosis.[148,164,152]
Kidney
In the kidney, blood passes through renal filtration structures called glomeruli
(which exclude material larger than 5-6 nm) and flows into tubules; fluid and metabolites
are then re-collected by renal veins, while remaining waste material flows through the
ureter into the bladder.[165] The kidney thereby collects nanomaterials that are smaller
than 5-6 nm (including high-aspect-ratio particles with two small dimensions). Notably,
small particles must also have low opsonization, or else they will likely be diverted by the
MPS.[146,165–167]
Diseased vasculature
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While vascular leakage is fundamental for the healthy filtration functions of the
mentioned organs, leaky endothelial beds can also arise in several diseased states. For
example, inflammation increases vessel permeability, which facilitates migration of
immune cells from blood into diseased tissue [168] and can also be exploited to deliver
nanotherapeutics.[169]
Abnormal vascular fenestrations are also famously associated with cancer. As
tumors grow beyond 2-3 mm in diameter and surpass limits for nutrient diffusion, they
must establish an independent blood supply. [168,170,171] However, this angiogenic process
is highly dysregulated, and the resulting vessels are often characterized by tortuous
branching, uneven dilation, abnormal deposition of mural cells and basement
membranes, and gaps between endothelial cells (most 1-100 nm, up to almost 5
µm).[172–175] Through these gaps, circulating nanomaterials can extravasate from the
bloodstream and into tumor tissue.[151] Furthermore, the intratumor environment typically
lacks functional lymphatic vessels,[176] so particles may not be able to drain away from
tissues quickly. These two phenomena are known collectively as the enhanced
permeability and retention (EPR) effect,[177] and are the theoretical basis for the
observation that long-circulating nanomaterials can accumulate in tumor tissue on the
basis of size alone. The majority of FDA-approved nanoparticles for oncology have
been designed based on this principle, without molecular targeting.
However, several challenges are associated with this strategy. It can be difficult
for particles to permeate far away from blood vessels – indeed, the lack of lymph
drainage within the tumor also causes high interstitial pressure that may prevent inward
diffusion of particles[178,179] This is especially important considering many tumors may
have large sections that are poorly vascularized, and some cancer types (e.g., prostate)
18

are prone to low vascular density overall.[179,180] Also, while particle accumulation may
be higher than that of small molecular compounds, the overall dose fraction delivered to
the tumor is often still quite low. In a landmark meta-analysis performed by Wilhelm et
al,[181] it was found that tumors received a median of only 0.7% of the injected dose.
Also, though EPR has been observed consistently in animal models, these may not
accurately reflect the typical clinical presentation, especially when xenograft models are
used for establishing tumors. In humans, the extent of EPR may be highly variable
between different tumor types, in different patients, in metastases, and even within a
single tumor.[182] Nevertheless, EPR can be an effective tool for delivery of
nanomaterials.
1.3.4 Degradation and elimination
By lysosomal pathways, a large portion of ingested material – including
nanomaterials – are degraded by the cell.[183] Nanoparticles and their breakdown
products can exit the body through renal and/or hepatobiliary excretion pathways. [184]
Particles that accumulate in the kidneys and pass through renal filters are then collected
in the urine, where they can be eliminated. [165] Within the liver, particles can be
endocytosed by hepatocytes; these cells periodically exocytose the contents of their
lysosomes into bile, which eventually carries this material into the duodenum and into
feces.[185–187] As mentioned, most particles that enter the liver are sequestered in Kupffer
cells (at least, preliminarily), and therefore must avoid or escape these cells in order to
undergo hepatobiliary excretion. Additionally, while renal clearance generally occurs
within minutes, hepatobiliary excretion has a timeline of weeks to months. [186]
Many organic materials are lysosomally digested. For example, dextran can
degrade over the course of several weeks, eventually being excreted through the
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urine.[188] Degradation of organic materials commonly occurs via lysosomal hydrolytic
enzymes, though they can also be degraded by reactive oxygen species; interestingly,
this process can take place intracellularly[189,190] or extracellularly.[191,192] Some inorganic
materials can be degraded within lysosomes, generally through acidic mechanisms. [193]
An excellent example is iron oxide nanoparticles; in vivo studies have demonstrated their
breakdown in lysosomes and incorporation into the body’s iron store – first in
intracellular ferritin, eventually in RBC hemoglobin – potentially without disrupting cellular
iron homeostasis.[188,194–196]
However, gold nanoparticles present a great challenge for biodegradation. They
have very limited breakdown within the body, and numerous studies have shown
persistence of gold for long timeframes in organs such as the liver.[197–200] It does appear
that some gold nanoparticle formulations can break down over time.[194] One proposed
mechanism is through etching by hydroxyl radicals, which can be produced by
macrophages;[201–203] it may also be possible for surface-bound thiols to dissociate from
gold cores and pull out individual Au atoms as they migrate.[204,205] Occasionally, the
robustness of gold has been utilized purposefully, such as to protect other nanomaterials
from degradation.[206] However, it is generally considered a hurdle for clinical
translation.[207,208]
1.3.5 Other physiochemical interactions
Stimulus-responsive nanoparticles
The complexity of biological systems presents unique challenges in that
materials must often navigate multiple compartments over time; a particle’s
physiochemical properties may be advantageous at one stage and unfavorable in
another. To address this issue, a number of reported nanoformulations have been
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designed to respond to environmental changes in order to produce different
spatiotemporal effects.
One source of useful triggers is the cohort of different physiochemical conditions
present within the body. For example, pH gradients exist between many tissues and
subcellular compartments. As previously mentioned, cellular endosomes and lysosomes
are typically acidic; solid tumors may also have reduced extracellular pH (as low as 6.5)
due to hypoxia, lactate production, and related effects. [209,210] Nanomaterials may
respond to these conditions through changes such as protonation or hydrolysis.[211,212]
Some examples of triggered effects include, but are not limited to: electrostatic swelling
or membrane fusion to rupture endosomes, [138,213] cleavage to release covalently-bound
drug cargo or expose surface ligands,[214,215] solubility transitions that allow dispersion of
cargo and/or particle degradation;[216,217] and aggregation or dissociation for tumor
retention or penetration, respectively. [218] In addition to pH-triggered events, many other
endogenous stimuli can be targeted to induce similar changes in particles. Within
tumors, stimuli could potentially include enzymes (especially proteolysis), [219–222] redox
changes (especially disulfide reduction), [223–225] and temperature (hyperthermia). [226]
Particles have also been designed to react to exogenously-applied triggers.
These often have the advantage of additional control over the site, time, and intensity of
administration. For example, rather than relying on the minor hyperthermia present in
some diseased tissue, temperature can be directly increased through mechanisms such
as highly-focused ultrasound.[227,228] Nanomaterials themselves may generate heat in
response to triggers like irradiation and ultrasound, [229–235] which can be used for
applications such as therapeutic tissue ablation or enhanced release of other cargo.
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Toxicity
As described in detail, nanomaterials interact uniquely with biological systems in
ways that are distinct from their composite materials’ molecular or bulk properties. This
principle applies to toxicity as well. Materials can have distinctive safety profiles based
on factors that include their physical presentation within a particle structure, their
combination with other incorporated substances, or their particle-related degradation
profiles. A number of studies have looked at the toxicity of gold nanoparticles, but it is
clear that results can vary widely.[200,236–238] General mechanisms of toxicity include
oxidative stress,[65,239,240] cytoskeletal changes,[65,239,240] upregulation of proinflammatory
cytokines,[241,242] and membrane lysis.[239] Toxicity can also be associated with
persistence of AuNPs within lysosomes; their presence may cause alkalization and
inhibition of lytic enzymes within lysosomes, and can disrupt autophagosome-lysosome
fusion.[243,244]
Unsurprisingly, toxicity appears to depend greatly on the surface coating of
particles. Several early studies demonstrating toxicity in gold particles – especially
nanorods – were ultimately found to be the result of surface-associated
cetyltrimethylammonium (CTAB), which is commonly used in particle synthesis and
which can cause mitochondrial damage and apoptosis.[245,246] In animal studies, citratecoated particles were found to be more biocompatible than particles coated with a
common solubilizing peptide, CALNN, which produced anemia and atrophy of the
spleen.[199] Notably, surface composition has a large impact on protein corona and on
membrane interactions, both of which can contribute to the apparent toxicity of particles.
For example, studies showed greater dose-dependent toxicity for cationic particles than
for anionic particles, but this may have been the effect of their greater cellular
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association and/or uptake.[65,239] An interesting study by Soenen et al[240] also reported
that positively-charged particles could induce toxicity, while neutral PEG-coated particles
were less toxic; however, when data was normalized by intracellular nanoparticle levels,
PEGylated particles were found to have greater induction of ROS. Another property that
modulates toxicity is particle size, though these trends are especially variable between
studies; particles have been separately described as toxic only in the range of 8-37
nm;[247] only in the range of 1.2-1.4 nm;[248] or only below 6 nm.[241]
However, a large number of studies have found AuNPs to be generally
nontoxic.[59,237,249–251] Mouse studies using AuroVist™ (1.9-nm water-soluble AuNPs)
have reported an LD50 as high as 3.2 g kg-1 body weight.[252] Other studies have shown
excellent tolerance for chronic high doses of AuNPs (up to 550 µg kg-1 per day for up to
28 days).[253,254] One of the most comprehensive studies was performed by Gad et al, [198]
who tested PEGylated 155-nm gold shells (AuroLase®) and showed no acute or chronic
toxicity in mice or dogs. These data formed the basis for clinical trials involving
photothermal ablation of prostate tumors, and the particles’ clinical safety in patients was
confirmed.[255,256] Overall, it is clear that many AuNPs can exhibit excellent
biocompatibility, though new formulations must be rigorously tested.
1.4 Applications for gold nanoparticles in cancer
Cancer
Cancer, which is characterized as the malignant uncontrolled growth of cells,
remains one of the world’s leading causes of death. Treatment paradigms typically
include surgery to remove solid tumors, as well as a combination of chemotherapy and
radiation to induce cellular death. All three of these areas have been explored heavily in
nanoparticle applications, including image-guided surgery to reveal tumor location and
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define margins; delivery of toxic compounds to tumors; and localized radiation dose
enhancement.[257,258]
Breast cancer is the most common type of cancer in women, with 1.4 million new
cases diagnosed annually worldwide. [259] While the incidence of breast cancer has been
steadily increasing globally, it has decreased over the last decade in the United States.
This decrease correlates with the introduction of hormone-replacement therapy, which
has proven effective in treating estrogen receptor-positive tumors. However, nearly 1020% of tumors lack the ability to respond to hormone therapy. [260] These tumors tend to
be more aggressive, consequently requiring more aggressive regimens of cytotoxic
chemotherapy, surgery (where possible), and radiation. [261] The use of targeted
nanomedicines could potentially facilitate enhanced treatment of breast cancer without
increasing adverse side effects.[262,263]
1.4.1 Imaging applications
Computed tomography
Computed tomography, or CT, is a highly efficient and widely available tool for
imaging tumors and other biological tissues. [264] CT imaging involves the threedimensional reconstruction of images produced by x-rays. Tissues attenuate x-rays to
different degrees based on several factors including thickness and mass attenuation
coefficient; this value is derived from the photoelectric effect, which proportional to the
cube of the material’s atomic number (Z3). Many soft tissues are difficult to differentiate
due to their similar degrees of x-ray attenuation, but they can be distinguished by
administering contrast agents with variable distribution. Gold nanoparticles have
excellent potential as a CT contrast agent due to gold’s high atomic number (79) and
AuNPs’ distinct pharmacokinetics.[238,264,265] Early uses of AuNPs in x-ray imaging were
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reported in 2004 and 2006 by Hainfeld et al. [266,252] These studies using 1.9-nm AuNPs
produced detailed images of blood vessels (including vascularized tumors), with greater
and longer-lived sensitivity compared to the standard-of-care iodine-based contrast
agent. Many other AuNP formulations have since demonstrated good tumor
accumulation and contrast,[265] including those with[267–270] and without[271,272] molecular
targeting. These highly-effective contrast agents could ultimately improve patient safety
by allowing lower x-ray radiation doses.
Photoacoustic imaging
In photoacoustic imaging, or PA, a material is irradiated with pulsed light and the
absorbed energy is dissipated nonradiatively as heat. While the laser is applied (i.e.,
“during” the pulses), local temperatures increase and the material undergoes
thermoelastic expansion. Between pulses, the temperature drops and the material
contracts. These repeated pressure changes generate acoustic waves, which can be
detected as wideband ultrasonic emissions and eventually reconstructed into an image
of this region.[273,274] This imaging modality is commonly used to image endogenous
photoabsorbers, which can be distinguished based on their spectral signals; for
example, oxygenated and deoxygenated hemoglobin may be distinctly identified within
tissues for comparisons of relative concentration.
Many gold particles can be excellent PA contrast agents due to their strong
absorbance of light, though this absorbance depends strongly on particle size and
shape.[274,275] When imaging tissues, it is highly desirable to use contrast agents that
absorb in the near-infrared (NIR) range (approximately 650-110 nm); light in this window
has relatively low tissue absorption and therefore deeper penetration, which allows
deeper imaging.[276] This makes PA imaging one of the best and only ways to visualize
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deep tissues in real time. Furthermore, it does not require use of ionizing radiation, and
its instrumentation is becoming progressively cheaper and more accessible.[277,278]
These factors are likely to contribute to its increasing adoption in clinical settings.
Photoluminescence and quenching
Gold nanoparticles can exhibit a property known as surface plasmon resonance
(SPR).[11,279,280] A particle’s electron cloud (i.e., conduction electrons) can collectively
oscillate when excited at a specific frequency of light, resulting in strong absorbance at
that wavelength. This SPR absorbance peak is determined by the particle’s size, shape,
and other properties; for example, it does not occur at all in very small nanoparticles (< 2
nm). In general, when gold particles aggregate (or otherwise closely associate), their
absorbance spectrum will shift to reflect the SPR peak associated with the diameter of
the larger composite; this has been utilized as a mechanism to detect local changes. [281–
283,280]

Gold is capable of strongly quenching the fluorescence of nearby
materials.[284,285] This phenomenon can also be utilized as a reporter of molecular
conditions. For example, fluorophores can be conjugated onto AuNP surfaces using
environmentally-sensitive linkers; the dyes’ signals are quenched while bound to AuNPs,
but they will emit detectably when they are cleaved from gold. [286–288] When it is
desirable to reduce the quenching effects of gold within particles, materials like silica can
be installed as a buffer.[289,290] However, gold’s quenching ability may also improve its
utility in various applications, particularly those that rely on the nonradiative emission of
absorbed energy (e.g., photoacoustic imaging and photothermal therapy).
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1.4.2 Therapeutic applications
Radiation therapy
Radiation therapy is one of the primary clinical paradigms for cancer treatment,
indicated in approximately 50% of all cancer patients.[291] In this process, ionizing
radiation deposits energy into biological tissues and causes oxidation and fragmentation
of DNA, proteins, and membranes. This can occur directly when macromolecules
absorb the applied radiation, but most damage (~70%) derives from their secondary
reactions with ionized water or oxygen, i.e. reactive oxygen species. [292,293] DNA
damage, especially in the form of double-strand breaks, are difficult for cells to repair
and often result in cell cycle arrests and cell death. However, incorrectly repaired DNA
lesions might introduce new mutations, making it especially important that radiotherapy
delivers effective killing doses to malignant cells while avoiding delivery to healthy
tissues.[293]
Radiation is typically applied as convergent beams of photons (gamma or xrays). Another option, ion beam radiotherapy (e.g., protons), has gained increasing
clinical prevalence due to its greater spatial precision; as ions pass through tissue, most
of their energy is attenuated and deposited at a specific terminal distance termed the
Bragg peak, which can be focused to the tumor’s position. [293,294] Nevertheless, both
photon and ion therapies risk significant exposure of healthy tissue, particularly along
beam paths.
Tumor specificity can be improved by applying radiosensitizers, which increase
local energy deposition and/or vulnerability to damage.[295] Gold nanoparticles function
as potent radiosensitizers through a number of mechanisms. As mentioned previously,
gold’s high atomic number is associated with strong x-ray attenuation. Upon photon
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absorption, gold can eject secondary electrons, including A) inner-shell photoelectrons,
with accompanying Auger electrons, at lower (keV) photon energies; and B) outer-shell
Compton electrons at higher (MeV) photon energies (Figure 1.4).[295,296] Notably,
kilovoltage energies provide the greatest dose enhancement effect for gold over tissue,
though megavoltage provides deeper tissue penetration and is the current clinical
standard.[297] AuNPs can also absorb energy through intermediary water- and oxygenderived radicals, and this mechanism likely contributes strongly to the radiosensitization
effects observed in higher-energy photon therapy and in proton radiotherapy. [293,297] In
addition to emitting electrons, irradiated gold nanoparticles may increase generation of
reactive oxygen species through catalytic reactions.[295] Finally, AuNPs help confine the
dose delivery area by increasing radiation attenuation within the tumor environment,
reducing the fraction delivered to healthy tissues beyond and thereby improving safety
margins.[293,296,298]

Figure 1.4. Mechanisms of photon attenuation and secondary emission by radiosensitizers. Adapted by
permission from Laprise-Pelletier et al.[296]

Thermal therapy
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Hyperthermia is useful in several therapeutic applications, particularly in cancer,
where localized heat can generate cellular damage and allow partial or complete tissue
ablation.[299,300] Cell death typically occurs at temperatures beyond 41-45 °C, through
either apoptosis (mild heat) or necrosis (higher heat); high temperatures are typically
pursued in bulk tissues to ensure sufficient temperature over spatial gradients. [300]
Hyperthermia can also enhance the effectiveness of other therapeutic mechanisms. For
example, thermal stress induces protein damage that renders cells more susceptible to
damage from radiotherapy and chemotherapy; hyperthermia can also increase tumor
blood flow and thereby increase delivery of chemotherapeutic agents and
radiosensitizing oxygen.[301–303] Thermal destruction of cancer cells can also generate
and disseminate tumor antigens, while local inflammation stimulates immune recruitment
and activation, making hyperthermia a potential complement to immunotherapy.[300,304]
Localized deep tissue heating can be induced non-invasively through application
of ultrasound or long-wave electromagnetic radiation, which heat tissue directly.[305]
However, nanoparticle-mediated heating techniques typically offer greater treatment
precision both in uniformity and spatial resolution of tumor heating, thereby reducing
damage to off-target tissues.[303,306] As previously described, gold nanoparticles are
capable of absorbing optical energy and converting it into heat;[307] photothermal therapy
using gold nanoparticles and nanorods have been explored extensively since initial
studies in 2003[308] and 2006[230], respectively. Gold nanoparticles can also generate
heat by absorbing radiofrequency radiation, though this process is more poorly
understood and studied.[306,309]
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CHAPTER 2: BIODEGRADABLE GOLD NANOCLUSTERS FROM PH-SENSITIVE
ACETALATED DEXTRAN

2.1 Abstract
Gold is a highly useful nanomaterial for many clinical applications, but its poor
biodegradability can impair long-term physiological clearance. Large gold nanoparticles
(20-200 nm), such as those required for long blood circulation times and appreciable
tumor localization, often exhibit little to no dissolution and excretion. This can be
improved by incorporating small gold particles within a larger entity, but elimination may
still be protracted due to incomplete dispersion of gold. The present study describes a
novel gold nanoparticle formulation capable of environmentally-triggered decomposition.
Ultrasmall gold nanoparticles are coated with thiolated dextran, and hydrophobic acetal
groups are installed through direct covalent modification of the dextran. This
hydrophobic exterior allows gold to be densely packed within ~150-nm polymeric
micelles. Upon exposure to an acidic environment, the acetal groups are removed and
the gold nanoparticles become highly water-soluble, leading to destabilization of the
micelle. Within 24 hours, the ultrasmall water-soluble gold particles are released from
the micelle and readily dispersed. Micelle degradation and gold nanoparticle dispersion
was imaged in cultured macrophages, and micelle-treated mice displayed progressive
physiological clearance of gold, with > 85% elimination from the liver over three months.
These particles present a novel nanomaterial formulation and address a critical
unresolved barrier for clinical translation of gold nanoparticles.
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2.2 Introduction
Gold nanoparticles (AuNPs) are among the most extensively studied
nanoformulations, in part due to their easily manipulatable morphology and surface
chemistry as well as their potential to be used in a variety of clinical applications. [1–3]
Gold has attracted tremendous interest as a therapeutic agent – particularly in oncology
– for applications including radiation sensitization [4–6] and photothermal therapy.[7–9] It
has also been explored in various biomedical imaging modalities, including computed
tomography (CT),[10–12] photoacoustic imaging,[13,14] and surface-enhanced Raman
scattering.[15] Additionally, gold has been complexed with a range of other
pharmaceuticals and imaging agents, as a scaffold for targeted delivery and multimodal
activity.[12,16–18]
The ability of AuNPs and other nanoparticles to target specific biological
compartments is dependent on an optimized particle size (among other properties).
Formulating AuNPs of approximately 20-200 nm helps confer long serum circulation
times by avoiding rapid renal elimination.[19–21] This also allows particles to preferentially
localize to tumors via the enhanced permeability and retention effect (EPR), whereby
circulating nanoparticles can extravasate through leaky tumor vasculature and persist
due to poor lymphatic drainage.[22,23] However, long-circulating AuNPs can exhibit
impaired physiological clearance due to gold’s poor biodegradability. Gold particles
cannot be easily broken down, even within the lysosomal compartment’s highly acidic
and hydrolytic environment, though a few processes may contribute to the slow
degradation of gold over time (e.g., etching by thiols [24–26] or hydroxyl radicals[27,28]). As a
result, gold nanoparticles commonly persist in tissue for weeks to months. [29–31] For
example, in a landmark study by Sadauskas et al[32] in which 40-nm AuNPs were
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administered intravenously to mice, it was found that only 9% of gold was eliminated
from the liver over the course of six months. Similarly, preclinical studies of 150-nm gold
nanoshells showed no detectable reduction in total gold mass within the body, even at
more than one year post-injection.[29] The long-term persistence of gold nanoparticles
represents a significant concern for clinical applications and regulatory approval.[33,34]
In order to improve the clearance of AuNPs while maintaining favorable
pharmacokinetics, one strategy is to package clusters of small AuNP cores within a
larger biodegradable construct. Such nanomaterials may be fabricated at an overall size
that preserves favorable biodistribution, but the use of small gold particles can
accelerate degradation and excretion. This is because small hydrophilic AuNPs have
the potential to be renally excreted [35–38] and retained particles may have improved
deterioration due to their high surface-to-volume ratio.[30,39] Several such AuNP clusters
have been reported, using a variety of complexing materials (e.g.,
polyphosphazene,[40,41] polylysine and silica,[42] amphiphilic block copolymers containing
poly(ethylene glycol) and polylactic acid[43,44] or polycaprolactone,[45] liposomes,[46,47] and
oligonucleotides[48]).
Recently, our group reported gold-loaded polymeric micelles consisting of 1.9-nm
dodecanethiol-capped AuNPs encapsulated by poly(ethylene glycol)-block-poly(εcaprolactone) (PEG-PCL), with tunable micelle diameters of 30-150 nm.[49,50] The use of
hydrophobic AuNPs allowed facile particle synthesis through micelle self-assembly, and
dense packing of substantial gold mass within the particle core. These particles showed
excellent tumor accumulation, biocompatibility, CT contrast, and radiosensitization. The
use of small AuNPs conferred significant improvements in bioelimination compared to
large solid cores, with ~30% reduction in the liver from day 2 to day 7 post-injection. In
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later studies using 0.9-nm AuNPs, this was further improved to ~40% reduction in the
first week, and up to 65% over three months. [51] It was suspected that the residual
biopersistence of gold resulted from incomplete dispersion of the hydrophobic particles.
To that end, we have developed a novel gold nanomaterial that transitions from
hydrophobic to hydrophilic under acidic conditions (Figure 2.1). In particular, ultrasmall
gold nanoparticles are coated with the pH-sensitive polymer, acetalated dextran.[52] The
resulting particles can be encapsulated within the hydrophobic core of an amphiphilic
diblock copolymer, forming a tightly-packed polymeric micelle. Upon exposure to low pH
environments (e.g., the cellular lysosomal compartment), the pendent acetal groups on
the acetated dextran undergo hydrolysis, leading to disruption of the micelle and an
increase in AuNP hydrophilicity. These small, dispersed AuNPs have a greater capacity
for degradation and excretion, allowing for faster and more extensive bioelimination.

Figure 2.1. Schematic of AcetalDextran-AuNPs and AcetalDextran-AuNP-Micelles. Ultrasmall gold particles
are coated with a hydrophobic pH-sensitive polymer, acetalated dextran; upon exposure to low pH
environments, this hydrophobic coating becomes hydrophilic. Polymeric micelles encapsulating these
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materials will be stable at standard physiological pH but will dissociate within the lysosome, allowing
dispersion of soluble AuNPs.

2.3 Results and Discussion
A goal of this study was to produce dextran-coated gold nanoparticles that were
smaller than the cutoff for renal clearance (estimated at 5-10 nm), which necessitated
the production of even smaller AuNP cores (~2nm in diameter). To produce these
AuNPs, a protocol was adapted from Jadzinsky et al[53] using p-mercaptobenzoic acid as
the capping ligand; this reaction could be scaled to produce monodisperse 1.7-nm gold
particles at yields of several hundred milligrams (“pMBA-AuNPs”; Figure 2.2B). These
AuNPs were subsequently coated with a low-molecular-weight dextran (5 kDa) with a
single terminal thiol group (Figure 2.2A).
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Figure 2.2. Synthesis of AcetalDextran-AuNPs. (A) Dextran (5 kDa) was combined with 3,3'dithiobis(propanoic dihydrazide) to install a terminal thiol group. (B) Ultrasmall hydrophilic gold
nanoparticles (AuNPs) were synthesized using p-mercaptobenzoic acid (pMBA) as a capping ligand;
particles had a mean diameter of 1.7 ± 0.5 nm (SEM). Inset shows TEM image of dried particles. (C)
pMBA-AuNPs were coated with thiolated dextran via ligand exchange, yielding Dextran-AuNPs. (D)
Dextran-AuNPs were covalently modified with acetal groups, yielding AcetalDextran-AuNPs. (E)
Demonstration of water-soluble Dextran-AuNPs vs. chloroform-soluble AcetalDextran-AuNPs.

Thiolated dextran was prepared by reductive amination of the terminal glucose
moiety, which possesses a single transient aldehyde, with 3,3'-dithiobis(propanoic
dihydrazide). 3,3'-dithiobis(propanoic dihydrazide) contains two terminal hydrazide
groups and an internal disulfide. Hydrazide was chosen as the aldehyde linking group,
as opposed to a primary amine, because it is generally resistant to acidic hydrolysis,
especially when it is further stabilized by reduction with cyanoborohydride. [54,55] After
conjugation of the dihydrazide with two dextran molecules, the disulfide was reduced
with tris(2-carboxyethyl)phosphine (TCEP) to yield dextran-thiol, which was isolated by
washing in 90% methanol. Notably, disulfides are generally capable of binding gold
surfaces without prior reduction;[56,57] however, we found that the dextran disulfide dimer
could not be efficiently conjugated with gold, presumably due to steric occlusion.
AuNPs were coated with dextran-thiol through simple ligand exchange in
aqueous solution (“Dextran-AuNPs”; Figure 2.2C,E). The successful addition of dextran
was confirmed by analyzing the mass percentage of gold in purified particles: pMBAcoated AuNPs were approximately 80% gold, but this dropped to 31% gold after the
ligand exchange reaction, due to the larger size of dextran (Table 2.1). Dextran-AuNPs
were also examined by dynamic light scattering, and their average peak hydrodynamic
diameter was 7.3 nm, suggesting the possibility of renal filtration.
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pMBA-AuNPs

% Au [w/w]a

Core diameterb

79.3%

1.7 ± 0.5 nm

Hydrodynamic
diameterc

Solubilityd

pH sensitivitye

5.0 nm

Water

No

Water,
DMSO

No

n/a

Acetone,
Toluene,
Chloroform

Yes

146.0 nm

Water

Yes

PDI: 0.251
Dextran-AuNPs

31.0%

2.1 ± 0.5 nm

7.3 nm
PDI: 0.246

AcetalDextranAuNPs

13.8%

2.1 ± 0.6 nm

AcetalDectranAuNP-Micelles

11.4%

111.1 ± 38 nm

PDI: 0.156

Table 2.1. Physiochemical parameters for AcetalDextran-AuNP-Micelles and precursor gold nanoparticles.
a

Percent gold mass measured by ICP-OES. bCore diameters measured by transition electron microscopy,

expressed as the average of 40-100 particle measurements, ± standard deviation. cHydrodynamic
diameters measured by dynamic light scattering, expressed as the mean intensity and polydispersity index
averaged for three measurements (pMBA-AuNPs and Dextran-AuNPs, one batch; AcetalDextran-AuNPMicelles, six batches). dSolubility is not comprehensive. epH sensitivity refers to observed changes in
particle solubility and sedimentation behavior after incubation at pH 5.0.

After conjugation of AuNPs with dextran, the hydroxyl groups on the dextran
were covalently modified with pendant acetal groups (Figure 2.2D,E) to increase the
hydrophobicity of the particles and enable their encapsulation within micelles. To
append the acetal groups, Dextran-AuNPs were dissolved in dimethyl sulfoxide and then
directly chemically reacted with 2-methoxypropene in the presence of the catalyst
pyridinium-p-toluenesulfonate. The resulting particles, “AcetalDextran-AuNPs” (or
“ADAs”), were no longer soluble in water; instead, they could be dissolved in nonpolar
organic solvents such as chloroform and toluene. This, along with an additional
decrease in particle gold mass percentage (Table 2.1), was indicative of a distinct
compositional change from Dextran-AuNPs and strongly suggests the successful
application of acetal groups.
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The behavior of ADAs was characterized under acidic conditions to evaluate their
ability to transition back to hydrophilic Dextran-AuNPs. A range of aqueous buffers
representing various physiological compartments were tested: PBS, pH 7.4, for blood;
PBS, pH 6.8, for hypoxic tumors; and 0.3 M acetate buffer, pH 5.0, for lysosomes. First,
hydrophobic ADAs were suspended in each of these buffers, which initially formed a
turbid suspension due to the insolubility of these particles (Figure 2.3A,B). After several
hours of mixing at 37 °C, particles at pH 7.4 and 6.8 appeared to remain unchanged.
However, at pH 5.0, particles became fully water-soluble over the course of 12 hours, as
evidenced by a dramatic increase in solution transmittance from cloudy (7.4 %T) to clear
(60.7 %T). To further confirm this behavior, we suspended AcetalDextran-AuNPs in
serum at either pH 7.4 or pH 5.0 (Figure 2.3C). Initially, particles could be precipitated
by centrifugation, which indicated insolubility due to their hydrophobic acetal coating. At
later timepoints, particles at pH 5 lost this property and remained in solution even after
high-speed centrifugation (16,000 x g, 10 min). This shift in solubility is consistent with
the expected hydrolysis of the acetal groups at low pH.
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Figure 2.3. pH-dependent solubility of particles incubated at pH 7.4 (PBS), pH 6.8 (PBS), or pH 5.0 (0.3M
acetate). (A) AcetalDextran-AuNPs (ADAs) were suspended in buffers (1.5 mg mL-1 by dry particle weight)
and incubated at 37 °C under constant agitation for a total of 24 hours. Representative images shown. (B)
Aliquots of AcetalDextran-AuNPs were removed and measured for absorbance at 750 nm; results
expressed as percent transmittance, average of three measurements ± standard deviation. (C,D)
AcetalDextran-AuNPs or AcetalDextran-AuNP-Micelles (ADAMs) were suspended in serum (0.04 mg mL-1
by Au, 1 mL) and incubated at 37 °C under constant agitation for a total of 24 hours. Particles were
centrifuged at 16,000 x g for 10 minutes; separate tubes were prepared for each timepoint.

Next, the ADAs were encapsulated within polymeric micelles. As noted, we have
previously reported encapsulation of hydrophobic AuNPs using the biodegradable
amphiphilic block copolymer PEG-PCL.[49–51] Following a similar approach,
“AcetalDextran-AuNP-Micelles” (or “ADAMs”) were formed by simple mixing of PEGPCL and gold particles in toluene, followed by emulsion in water and evaporation of
toluene to drive micelle self-assembly (Figure 2.4A). Micelles were isolated by
centrifugal sedimentation to yield 146-nm water-soluble particles (Figure 2.4B). Particle
structure and size were confirmed by transition electron microscopy imaging (both
standard- and Cryo-TEM) (Figure 2.4C). Micelles were observed to be stable in
phosphate-buffered saline (PBS) at 4 °C for at least one week, as evidenced by
consistent hydrodynamic diameter and EM structure (Figure 2.4D).
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146.0 nm
PDI: 0.156

Figure 2.4. Formation of AcetalDextran-AuNP-Micelles. (A) AcetalDextran-AuNPs and PEG-PCL were
dissolved in toluene and then suspended in water to form an emulsion, driving self-assembly of
AcetalDextran-AuNP-Micelles. (B) Hydrodynamic diameter of micelles determined via dynamic light
scattering. The average peak hydrodynamic diameter was 146 nm (average of six batches). (C) Electron
microscopy imaging of micelles in water via Cryo-TEM and standard TEM. (D) Hydrodynamic diameter of
micelles in PBS at 4 °C, recorded immediately after dissolution and at 1 hour, 1 day, 3 days, 5 days, and 7
days (average of three measurements, ± SEM). At 7 days, the sample was diluted 10-fold in water to
reduce salt concentration and then imaged by TEM (inset).

To determine whether the ADAs could undergo a similar transition at pH 5 (i.e.,
going from hydrophobic to hydrophilic) after being encapsulated in micelles, ADAMs
were dissolved in serum at either pH 7.4 or pH 5.0 (Figure 2.3D). Although the micelles
were fully soluble due to their outermost layer of PEG, their heavy gold cores meant they
could be pelleted out of solution by high-speed centrifugation (16,000 x g, 10 min).
When the micelles were mixed at 37 °C for 24 hours, those kept at pH 7.4 continued to
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display the same behavior, and could be pelleted. In contrast, those exposed to acidic
conditions could no longer be sedimented at these centrifugation speeds. This suggests
that the AuNPs no longer form a heavy gold core within the micelle and is consistent
with our proposed model: the acidic environment leads to hydrolysis of the acetal
groups, destabilization of the micelle core, and release of the Dextran-AuNPs.
Importantly, this phenomenon can apparently occur without the need for degradation of
the PEG-PCL, which is not expected to occur quickly under these conditions. [58]
We next examined the behavior of ADAMs in biological systems. Acetalated
dextran has previously been proven to have toxicity comparable to that of poly(lactic-coglycolic acid), an FDA-approved material; safety was confirmed in particle form and for
the isolated breakdown products of acetal hydrolysis (i.e., acetone and methanol). [52] To
confirm this behavior in the present formulation, ADAMs were incubated with an
immortalized human liver cell line, HepG2, and a standard MTT assay was performed
after 24 hours (Figure 2.5A). Cell viability of ~95% was seen up to at least 10 µg mL -1
gold, with no statistically significant decrease. Even at very high concentrations (80 µg
mL-1 Au), cells preserved more than 80% viability compared to media-only controls,
suggesting good biocompatibility.
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Figure 2.5. AcetalDextran-AuNP-Micelles (ADAMs) in cell culture. (A) ADAMs were incubated with HepG2
human liver cells at various concentrations (expressed as µg mL-1 Au) for 24 hours, and cytotoxicity was
assessed by MTT assay. % Cell viability was calculated in relation to media-only controls; statistical
comparison was performed using one-way ANOVA with post-hoc Tukey HSD test; *p < 0.05 relative to
media controls. (B,C) ADAMs or control micelles (C12-AuNP-Micelles) were incubated with RAW 264.7
murine macrophages at 10 µg mL-1Au for 24 hours. Cells were fixed and imaged by electron microscopy.
Single cell shown for each condition, with expanded images on left.
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The biodegradation of ADAMS was also assessed in cell culture. As a control for
these experiments, we prepared equivalent AuNP-loaded polymeric micelles that lacked
pH sensitivity: 2-nm dodecanethiol-coated AuNPs (“C12-AuNPs”) formed into micelles
using PEG-PCL (“C12-AuNP-Micelles”).[49] Each micelle formulation was incubated with
RAW 264.7 murine macrophages for 24 hours at 10 µg mL -1 gold; cells were then fixed,
embedded, and sectioned for TEM analysis (Figure 2.5B,C). AuNPs could be clearly
visualized within unstained cells and were localized to vesicular compartments. The pHsensitive ADAMs showed considerable breakdown of the spherical micelle structure and
dispersion of individual AuNPs. In contrast, control C 12-AuNP-Micelles retained a
distinctly spherical shape; although some separated AuNPs could be observed, the clear
unidirectional distribution pattern strongly suggested that this was an artefact of the TEM
tissue-sectioning process. At this 24-hour timepoint, both micelle formulations had
equivalent accumulation of gold within (or associated with) cells (ADAMs: 10.7 x10-9 µg
per cell; C12-AuNP-Micelles: 9.84 x10-9 µg per cell).
Finally, the pharmacokinetics of ADAMs was evaluated. C57 black mice were
injected intravenously with AcetalDex-AuNP-Micelles at a dose of 100 mg Au per kg
body weight. To determine the circulation time of micelles in the bloodstream, blood
samples were drawn at various timepoints post-injection and analyzed for gold content.
Micelles displayed long circulation, with a half-life of approximately 3.5 hours (Figure
2.6A).
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Figure 2.6. In vivo pharmacokinetics and biodistribution of AcetalDextran-AuNP-Micelles. Mice were
injected intravenously with 100 mg Au per kg body weight, and samples were collected at various timepoints
post-injection (n = 3 mice per timepoint, expressed as average ± SEM). (A) Blood samples were analyzed
by ICP-OES to determine gold content; curve-fitting performed using MATLAB software. (B) Tissue and
fluid samples were analyzed by ICP-OES to determine gold content (n = 3 mice per timepoint, expressed as
average ± SEM.) Statistical comparison was performed using one-way ANOVA with post-hoc Tukey HSD
test; *p < 0.05 relative to measurement at 1 day. (C) Urine was collected at 24 hours post-injection, diluted
1:1 in pure water, and imaged by electron microscopy. Electron-dense 2-nm particles are consistent with
the appearance of Dextran-AuNPs.
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A biodistribution analysis was performed by collecting organ samples at various
timepoints for a total of twelve weeks and assessing tissue gold content using
inductively-coupled plasma optical emission spectroscopy (ICP-OES) (Figure 2.6B).
ADAMs displayed a tissue biodistribution pattern that is typical for nanoparticles of this
size, with the majority of particles initially accumulating in the liver and spleen. However,
we observed a substantial drop in gold levels in these organs over time. On average,
liver gold decreased 86.1% over twelve weeks, while in the spleen it dropped 72% over
that period. Liver clearance was also more rapid; levels began to decrease appreciably
after the first week, while spleen levels remained high for the first four weeks. The
mechanisms of micelle elimination were not examined in detail, but they likely involve
endocytic uptake into cells, trafficking to lysosomes and other endosomal compartments,
and exocytosis. In the liver, hepatocytes periodically exocytose their lysosomal contents
into bile, where it is carried to the digestive tract and excreted in feces.[59–61] An
appreciable amount of gold was detected in the feces, particularly at 1 day postinjection. This hepatobiliary excretion route may contribute to the faster elimination of
gold from the liver vs. the spleen, where no equivalent system exists.
Notably, by ICP-OES analysis, elemental gold could also be detected in the urine
at 24 hours post-injection (%ID/g tissue: 4.5 ± 0.5). We further explored this
phenomenon by TEM imaging of urine samples (Figure 2.6C). We observed electrondense 2-nm particles that were well-dispersed and consistent in appearance to pMBAAuNPs and Dextran-AuNPs. These data confirm that intravenously injected
AcetalDextran-AuNP-Micelles are capable of breaking down into renally excretable
particles.
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Throughout these studies, we examined mice for signs of drug-induced toxicity.
Animals remained energetic and without visible signs of poor health (lethargy, noticeable
changes in food intake, poor grooming, etc.). Injected animals displayed an initial
transient drop in body weight (10%), which may have been caused in part by the stressinducing effects of intravenous injection, repeated blood collection, and other handling
procedures; this weight loss was resolved by day 4, and generally increased throughout
the twelve-week study (Figure 2.7A). Knowing the potential for high liver accumulation
of particles, serum was collected from mice at 1, 3, and 7 days post-injection and
analyzed for elevated liver enzymes: alanine transaminase (ALT), aspartate
transaminase (AST), and alkaline phosphatase (ALP) (Figure 2.7B-D). These levels
were widely recorded to be within normal limits, with the single exception of increased
AST at 1 day. Notably, these assays involve colorimetric detection of enzymes;[62] at the
1 day timepoint, serum contained a substantial volume of gold particles that imparted a
noticeable brown hue, which may have impacted analysis. Finally, tissue samples were
harvested from the kidney, liver, spleen, and lung at various timepoints post-injection
(Figure 2.7E). Tissues were embedded with paraffin, stained with hematoxylin and
eosin (H&E), and imaged by light microscopy. Liver glycogen depletion was observed at
Day 1, consistent with transient animal fasting; this correlates with the weight loss seen
at Day 1, and as noted, may arise partially from general animal handling stress.
Histological examination revealed no signs of acute or chronic pathology (apoptosis,
immune cell infiltration, damage to tissue architecture, etc.), with the exception of mild
spleen inflammation at Day 1, which diminished at 1 week and resolved by 3 months.[63]
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Figure 2.7. Safety profile of AcetalDextran-AuNP-Micelles after injection of 100 mg kg-1 Au. A) Percent
change in mouse body weight over time, normalized to pre-injection weight. B-D) Serum measurements of
alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase at various times postinjection. Gray shading represents standard clinical range for healthy mice. n = 3 mice per group, ± SEM.
E) Representative histological images of mouse organ tissues at various timepoints post-injection. Tissues
were paraffin-embedded and stained with H&E.
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2.4 Conclusion
Considering the extent of global research interest in gold nanoparticles and their
therapeutic potential, it is important to address the lingering question of their
physiological persistence. The reported strategy seeks to improve clearance while still
maintaining favorable aspects of gold particle design. This has been achieved by
utilizing a pH-sensitive polymer, acetalated dextran, which transitions from hydrophobic
to hydrophilic in acidic conditions. Acetalated dextran containing a single terminal thiol
group has been installed onto ultrasmall AuNPs using newly-described synthetic
strategies. Clusters of these particles could then be encapsulated within polymeric
micelles of favorable size, with high stability at pH 7.4. However, both the hydrophobic
AuNPs and their larger polymeric assemblies showed rapid degradation in acidic buffers
(pH 5.0) and in macrophage cell culture. Micelles were found to have good
biocompatibility and serum pharmacokinetics; furthermore, they displayed progressive
long-term clearance from accumulated tissues, including the liver and spleen.
Collectively, these environmentally-responsive materials present an intriguing and
effective strategy for the biodegradation of gold nanostructures.
2.5 Experimental Section
Materials: Dextran (5 kDa, T5) was purchased from Phamacosmos. 3,3’dithiobis(propanoic dihydrazide) was purchased from Frontier Scientific. Tris(2carboxyethyl(phosphine) (TCEP), gold(III) chloride trihydrate, tetraoctylammonium
bromide, 1‐dodecanethiol, sodium borohydride, pyridinium-p-toluenesulfonate, and 2methoxypropene were purchased from Sigma Aldrich. p-mercaptobenzoic acid (pMBA)
was purchased from TCI America. Sodium cyanoborohydride, triethylamine, fetal bovine
serum (FBS), Dulbecco's Modified Eagle Medium (DMEM), Trypsin‐EDTA, and
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penicillin–streptomycin solution were purchased from Thermo Fisher Scientific.
Poly(ethylene glycol)4000‐b‐poly(ε‐caprolactone)3000 (PEG‐PCL) was purchased from
Polymer Source. PBS (1X, pH 7.4) was purchased from Quality Biological. MTT assay
kit was purchased from Roche Diagnostics GmbH. Isoflurane was purchased from
Akorn Animal Health.

Synthesis of pMBA-AuNPs: Hydrophilic gold nanoparticles coated in p-mercaptobenzoic
acid (pMBA) were prepared using a protocol modified from Jadzinsky et al. [53] Briefly, a
stock solution of gold(III) chloride trihydrate (1 g mL -1) was first centrifuged for 30
minutes at 16,000 x g to remove gold crystals, and then 400 µL was added to an acidwashed flask and diluted in water (158 mL). 184 mL methanol was then added under
vigorous stirring. In parallel, pMBA was prepared as a 95 mM stock solution (726 mg in
50 mL) containing 300 mM sodium hydroxide (595 mg), and then combined with the
primary gold solution. The resulting solution was allowed to equilibrate for 3-5 hours,
until the color had changed from pale orange to nearly colorless. Next, a freshlyprepared 150 mM solution of sodium borohydride (159 mg in 28 mL water) was added to
the reaction dropwise over the course of 15 minutes, resulting in a gradual color change
to brown and then black over the course of 2 hours. The solution continued stirring
overnight. Particles were then precipitated by adding methanol (467 mL) and an
aqueous solution of sodium chloride (6.825 g in 47 mL) to the reaction mixture, then
centrifuging at 3000 x g for 5 minutes. To wash particles, pellets were first suspended in
70% methanol (v/v) and centrifuged again; next, pellets were dissolved in water and
rinsed repeatedly using centrifugal filters (10,000 MWCO, Amicon). Finally, particles
were added to pre-weighed microcentrifuge tubes and then dried under centrifugal
evaporation (Labconco).
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Synthesis of thiolated dextran: Thiolated dextran was prepared by reductive
amination.[55] Dextran (5 kDa; 14.163 g) and 3,3’-dithiobis(propanoic dihydrazide) (270
mg) were dissolved in 300 mL acetate buffer (0.3 M, pH 5). Sodium cyanoborohydride
(approximately 2.6 g) was then added, and the reaction was allowed to stir for 24 hours.
Next, a solution of TCEP (460 mg in 7 mL water) was brought to pH 5 using sodium
hydroxide, then added to the primary reaction solution. After 6 hours stirring, thiolated
dextran was purified as follows. First, the solvent was removed by lyophilization
(Labconco) and the solid product was ground to a fine powder. Next, solids were
washed four times by suspension in 90% methanol (v/v) followed by centrifugation;
between washes, pellets were mechanically disturbed either by agitating with a spatula
(after first two washes) or by drying the pellet under vacuum and re-pulverized (after the
third wash). Finally, the product was dried under vacuum.

Synthesis of Dextran-AuNPs: pMBA-AuNPs were dissolved in aqueous solution at a
concentration of approximately 2 mg mL-1 (by dry nanoparticle weight). Thiolated
dextran was added at approximately 10x molar equivalents relative to the pMBA ligand
(1 part pMBA AuNPs : 85 parts Dext-SH, w:w; calculated by approximating AuNP mass
percentage at 25% pMBA, and approximating molecular weight of thiolated dextran at
5239 Da). The reaction was stirred for 48 hours, and then purified by repeated washing
using centrifugal filters (30,000 MWCO). Finally, the resulting dextran-coated AuNPs
were lyophilized.

Synthesis of AcetalDextran-AuNPs: Dextran-AuNPs were acetalated using a protocol
adapted from Bachelder et al.[52] A 20-mL long-necked air-free flask was flame-dried
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under vacuum and then charged with nitrogen. Meanwhile, Dextran-AuNPs (up to 500
mg) were dissolved in 10 mL anhydrous DMSO, then combined with 16 mg pyridinium-ptoluenesulfonate; this was transferred anaerobically to the reaction flask. 3.4 mL of 2methoxypropene was then injected into the same flask, which was allowed to stir for 3
hours at room temperature under oxygen-free conditions. The reaction was quenched
by addition of 1 mL triethylamine. To purify, the solution was diluted into 100 mL water,
and approximately 10% volume was removed by rotary evaporation to ensure
elimination of excess triethylamine. The solution was then centrifuged at 3000 x g to
collect precipitates. Any solids that remained in the original reaction vessel or in the
flask used for rotary evaporation were washed with water. Finally, all precipitates were
dissolved in acetone, combined, transferred into pre-weighed microcentrifuge tubes,
then dried under centrifugal evaporation.

Synthesis of AcetalDextran-AuNP-Micelles: A solution was prepared containing 80 mg
mL-1 of Acetal-Dextran-AuNPs (by dry particle weight) and 40 mg mL-1 of poly(ethylene
glycol)-block-poly(ε-caprolactone) (PEG4000-PCL3000). After thorough sonication, 100 µL
of this solution was injected slowly into a glass scintillation vial containing 4 mL water
under constant sonication (Branson, bath sonicator); sonication continued until a
homogenous emulsion was formed. Vials were lightly capped and placed under vacuum
overnight to remove toluene, allowing formation of stable micelles. Micelles were
purified by centrifugation, first at 400 x g (10 minutes) to eliminate large precipitating
aggregates and then at 16,000 x g (30 minutes) to sediment micelles. This precipitate
was then collected and further concentrated using centrifugal filters (100,000 MWCO).
Particles were then stored at 4°C, typically after suspending in PBS (by adding 10x
concentrate).
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Synthesis of C12-AuNPs and C12-AuNP-Micelles: Gold nanoparticles and gold-loaded
polymeric micelles were synthesized as non-pH-sensitive experimental controls.
Dodecanethiol-coated AuNPs (C12-AuNPs) were synthesized using the Brust method,[64]
as adapted by Higbee-Dempsey et al.[65] Dodecanethiol-coated AuNPs were then
loaded into polymeric micelles using a protocol modified from by Al Zaki et al. [49,51] PEGPCL (17 mg mL-1) and dodecanethiol AuNPs (17.5 mg mL-1 by dry particle weight) were
dissolved in a total of 200 µL toluene. This solution was sonicated and then injected into
4 mL water to form a homogenous emulsion. Purification then proceeded as described
for AcetalDextran-AuNP-Micelles.

Particle characterization: Gold nanoparticles were characterized using a variety of
physiochemical methods. Particles were imaged by electron microscopy using a Tecnai
T12 microscope to determine gold diameter and overall particle morphology; size
analysis was performed using ImageJ software. Hydrodynamic diameter and zeta
potential were measured using a Zetasizer Nano ZS (Malvern Panalytical); data are
generally expressed as the average of triplicate measurements of one synthetic batch;
while data for AcetalDextran-AuNP-Micelles represent an average of six batches. Gold
concentration was determined using inductively-coupled plasma optical emission
spectroscopy (ICP-OES) on a Spectro Genesis. To prepare samples for ICP-OES,
solutions were placed in borosilicate glass tubes containing up to 1 mL of freshlyprepared aqua regia (a 1:3 mixture of nitric acid and hydrochloric acid; e.g., 250 µL
HNO3 and 750 µL HCl); tubes were lightly sealed with PFTE-lined caps, allowed to stand
for at least 20 minutes to ensure complete dissolution of gold, and then diluted in water
up to a known volume.
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Evaluation of acid-responsiveness: AcetalDextran-AuNPs were first dissolved in
acetone and then diluted into buffered solutions at one of three pHs: pH 7.4 (PBS); pH
6.4 (PBS, titrated to 6.8 using 1 M sodium hydroxide); or pH 5.0 (acetate buffer, 0.3 M).
All solutions consisted of 1.5 mg mL -1 AuNPs (by dry particle weight) and 2% acetone
(v/v). Solutions were placed at 37 °C and agitated vigorously using an orbital shaker.
Every 1.5 hours, triplicate aliquots were removed and analyzed. Absorbance was
measured at 750 nm (Tecan) to determine solution turbidity, as calculated using the
following equation:

% Transmittance = antilog (2 – absorbance)

(1)

Samples were then diluted to a concentration of 1 mg mL-1 and photographed.
In separate experiments, AcetalDextran-AuNPs and AcetalDextran-AuNPMicelles were examined in serum. First, fetal bovine serum was sterilely titrated to pH
5.0 using hydrochloric acid; this serum and unmodified serum were equilibrated at 4 °C
overnight, and then centrifuged at 3000 x g for 30 minutes to remove any aggregated
proteins. Gold particles were then sterilely dissolved in both serums at a concentration
of 0.04 mg mL-1 by Au, and divided into two 1.5-mL sterile microfuge tubes per
experimental group (1 mL each). One set of tubes were immediately centrifuged at
16,000 x g for 10 minutes, and pellets were photographed; the other set of tubes were
incubated at 37°C for 24 hours under constant agitation, then similarly centrifuged and
photographed.
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Cell culture: RAW 264.7 and HepG2 cells were acquired from ATCC. Cells were grown
at 37°C with 5% CO2 in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with
10% fetal bovine serum and 1% pen strep. Cell passage numbers were kept low (< 10)
to prevent genetic drift; during passage, RAW 264.7 cells were dissociated using cell
scrapers, while HepG2 cells were dissociated with trypsin-EDTA.

Determination of cell viability: HepG2 human liver cancer cells were examined by MTT
assay to determine cell viability. Cells were first seeded in a 96-well plate (1 x 105 cells
per well). The following day, media was carefully removed by pipette and replaced with
100 µL fresh media containing AcetalDextran-AuNP-Micelles at concentrations ranging
from 0 to 80 µg mL-1 (by Au concentration). Cells were incubated for 24 hours, after
which the media was removed and wells were washed with 200 µL PBS. Finally, cells
were given fresh media containing 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT). The MTT assay then proceeded according to the manufacturer’s
instructions. Cell viability was normalized to untreated control cells, and all conditions
were performed in triplicate wells.

Imaging cell uptake: To examine cellular uptake of AcetalDextran-AuNP-micelles,
particles were incubated with RAW 264.7 mouse macrophages. Cells were first seeded
in 6-well plates (2 x 106 cells per well, quadruplicate conditions). The following day,
media was carefully removed by pipette and replaced with 1 mL fresh media containing
micelles at a concentration of 10 µg Au per mL. In parallel control experiments, cells
were treated with 10 µg/mL C12-AuNP-Micelles. After 24-hours incubation, media was
carefully collected by pipette and set aside; cells were then gently washed with 1 mL
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PBS, which was also collected. An additional 1 mL PBS was then added, and adherent
cells were gently harvested using cell scrapers.
Cells were then examined using several techniques. In one set of experiments,
cells (3 wells each) were counted using a hemocytometer, transferred into pre-weighed
centrifuge tubes, weighed again, and lyophilized until dry. Dry tubes were weighed a
final time, and then solids were dissolved in 1 mL aqua regia and processed for ICPOES analysis as described. Tube weights were used to calculate exact number and
mass of cells.
In another set of experiments, washed cells (1 well each) were centrifuged at 500
x g for 5 minutes, and cell pellets were gently resuspended in 100 µL of fixative solution
containing 2% glutaraldehyde and 2% paraformaldehyde (w/v). Cells were then
prepared for EM imaging by the University of Pennsylvania Electron Microscopy
Resource Lab, and imaged on a JEOL 1010 microscope.

Animal welfare statement: Female C57BL/6 mice (6-8 weeks old) were obtained from
Charles River. All animals were housed and maintained according to procedures
approved by the University of Pennsylvania Institutional Animal Care and Use
Committee. Mice were fed nutritionally standard chow containing fenbendazole, with
free access to food and water.

Biodistribution and safety of AcetalDextran-AuNP-Micelles: Mice were intravenously
injected with AcetalDextran-AuN-Micelles at a concentration of 100 mg Au per kg body
weight (n = 18 mice total). Blood samples were then collected from the opposite tail vein
at the following timepoints: 2 hours, 6 hours, 24 hours, and 72 hours. At each timepoint,
approximately 10-25 µL were removed from each of three mice, which were randomized
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such that every mouse underwent no more than 3 blood draws in total. Whole blood
samples were then analyzed by ICP-OES as described, by digestion in 1 mL aqua regia
for a minimum of one hour. Half-life of gold in blood samples was determined by fitting a
double exponential decay curve to the data using MATLAB software (Mathworks).
Mice were then sacrificed at various timepoints post-injection: 1 day, 3 days, 1
week, 2 weeks, 4 weeks, and 12 weeks (n = 3 mice per group). Prior to sacrifice, urine
and feces samples (12-130 µL and 18-75 mg, respectively) were collected from lightlyscruffed mice. Mice were then anesthetized with isoflurane (3%, 1.5 L min-1 O2), and a
minimum of 500 µL blood was collected via cardiac puncture. Mice were euthanized by
cervical dislocation, and the following organs were harvested: brain, heart, kidney, liver,
lung, muscle, skin, and spleen. Organs were lightly rinsed in PBS immediately following
extraction.
At days 1, 3, and 7, cardiac blood was centrifuged to collect serum and then
analyzed for liver enzymes by the Penn Vet Clinical Pathology Diagnostic Lab. At day 1,
urine (n = 1 mouse) was examined by TEM imaging; 5 µL of urine was diluted 1:1 with
water and placed onto a TEM grid for 3 minutes, then grids were lightly blotted, allowed
to air-dry, and imaged using a Tecnai T12 microscope.
Feces, urine, and organ samples were analyzed by ICP-OES as described, by
digestion in 1 mL aqua regia for a minimum of 12 hours. Several tissue samples were
reserved for histological evaluation at 1 day, 1 week, and 3 months: kidney (n = 3 per
timepoint), liver (n = 3), spleen (n = 3), and lung (n = 1). Sections of these tissues were
fixed in formalin; paraffin embedding was performed by the Penn Center for
Musculoskeletal Disorders Histology Core, while sectioning and staining was performed
by the Penn Vet Comparative Histology Core. All samples were then imaged using an
EVOS light microscope and were examined for signs of pathology. At day 1, separate
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liver tissue sections were also preserved for examination of ultrastructure by electron
microscopy. These were suspended in 100 µL of fixative solution containing 2%
glutaraldehyde and 2% paraformaldehyde (w/v), and prepared for EM imaging by the
University of Pennsylvania Electron Microscopy Resource Lab; imaging was performed
on a JEOL 1010 microscope.

Statistical analysis: Statistical analysis was performed using one-way ANOVA with posthoc Tukey HSD test, using Astatsa online software (http://astatsa.com).
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CHAPTER 3: INDOCYANINE GREEN-COATED GOLD NANOCLUSTERS FOR
PHOTOACOUSTIC IMAGING AND PHOTOTHERMAL THERAPY

3.1 Abstract
Traditional oncology treatment modalities are often associated with a poor
therapeutic index. This has driven the development of new targeted treatment
modalities, including several based on the conversion of optical light into heat energy
(photothermal therapy, PTT) and sound waves (photoacoustic imaging, PA) that can be
applied locally. These approaches are especially effective when combined with
photoactive nanoparticles that preferentially accumulate in tissues of interest and
thereby further increase spatiotemporal resolution. In this study, two clinically-used
materials that have proven effective in both PTT and PA – indocyanine green and gold
nanoparticles – were combined into a single nanoformulation. These particles, “ICGAuNP clusters”, incorporated high concentrations of both moieties without the need for
additional stabilizing or solubilizing reagents. The clusters demonstrated high
theranostic efficacy both in vitro and in vivo, compared with ICG alone. Specifically, in
an orthotopic mouse model of triple-negative breast cancer, ICG-AuNP clusters could be
injected intravenously, imaged in the tumor by PA, and then combined with near-infrared
laser irradiation to successfully thermally ablate tumors and prolong animal survival.
Altogether, this novel nanomaterial demonstrates excellent therapeutic potential for
integrated treatment and imaging.
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3.2 Introduction
Radiation therapy has long represented a paradigm in the treatment of cancer,
with multiple advantages including efficacy against many tumor types and localized
delivery.[1–3] Traditional radiation therapy involves the use of high-energy ionizing
radiation – typically photons or charged particles – that relies on the inherent absorptive
properties of that tissue to deposit energy. However, this broad cytotoxicity may
contribute to inadvertent damage of adjacent healthy cells, particularly tissue in the path
of radiation. Ionizing radiation is also a critical component of computed tomography (CT)
and other imaging modalities used to clinically visualize malignant tissue; though dosage
is usually low, these procedures may themselves pose risks to normal biological tissue. [4]
A new class of therapies and diagnostics have emerged that harness lowerenergy forms of radiation, including infrared and visible light.[5–9] While less harmful to
tissues on their own, these can be applied in combination with localized exogenous
agents that mediate and enhance tissue interactions, thereby achieving site-specific
efficacy with reduced damage to off-target tissues. In particular, near infrared light (NIR,
650 – 1350 nm) is a highly attractive radiation source primarily due to its relatively deep
tissue penetration – up to several centimeters – compared to lower-wavelength light.[10,11]
NIR photomedicine has been broadly applied in cancer treatment and imaging through
numerous modalities,[8] including: photodynamic therapy, or PDT (light excites a
photoactive agent to a triplet excited state, which then directly or indirectly generates
free radicals and/or reactive oxygen species); photothermal therapy, or PTT (absorbed
energy is emitted as vibrational energy – i.e., heat); fluorescence imaging (energy is
emitted radiatively as a photon); and photoacoustic imaging (energy is emitted as heat,
which generates a detectable acoustic wave). Photoacoustic imaging has become
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increasingly popular due to its deep signal penetration (≤ 5-6 cm), high resolution (≥
5µm), and decreasing instrument costs. [12–16] Furthermore, because the molecular
contrast agents for photoacoustic imaging are optimized for non-radiative emission,
many of these same materials can be utilized for photothermal therapy, allowing dual
clinical functionality.[9] PTT has a potential advantage over photodynamic therapy, in
that it does not require the presence of oxygen, the concentration of which may be
limited in large solid tumors.[17]
To take advantage of photomedicine’s increased safety margin, it is necessary
for a photoactive moiety to be localized to the tumor tissue; however, this can be difficult
to achieve for many traditional small molecule agents. Nanoscale formulations may be
particularly useful for overcoming these targeting limitations. Due to their unique
physical, chemical, and biological properties, nanoparticles can: 1) deliver high volumes
of cargo to regions of interest, 2) maintain cargo in a desired site at an optimal time
period for clinical intervention, and 3) reduce cargo accumulation in off-target sites.[18]
An excellent candidate for nanoformulation – with great potential in both PTT and
photoacoustic imaging – is indocyanine green (ICG), which at present is the only FDAapproved near-infrared dye.[19,20] As a small molecule, ICG’s utility is limited because of
its instability in aqueous solution – especially when combined with light, heat, or salts –
as well as its rapid clearance from the bloodstream, which can prevent the high,
localized concentrations desirable for intervention in tumors. While these shortcomings
would likely improve in a nanoformulation, ICG can be difficult to load in large quantities
due to its amphiphilicity and lack of easily-modifiable chemical groups.
Recently, we reported several novel fluorophore-based nanoparticle structures
wherein a dye – ICG, protoporphyrin IX, or chlorin e6 – was combined with only one
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other common component: superparamagnetic iron oxide nanoparticles (SPIOs). [21–23] In
these three structures, the amphiphilic dye molecules were utilized as an outer coating
to stabilize clusters of hydrophobic SPIO particles, thereby thermodynamically driving
ICG to remain bound in large concentrations. The ICG-SPIO nanoclusters were
successfully employed in image-guided surgery based on photoacoustic imaging (of
ICG) and pre-surgical MR imaging (of SPIOs). However, in all of these studies, SPIOs
were utilized for MR imaging and as a scaffold for the amphiphilic dye, but were not
designed to contribute directly to tumor therapy.
With this in mind, we sought to further expand the utility of ICG clusters by
creating an inherently theranostic nanoformulation for combined photoacoustic imaging
and photothermal therapy, whereby both materials were capable of contributing to each
modality. For this, we selected another material that has been proven dually efficacious
in both photothermal therapy and photoacoustic imaging: gold nanoparticles
(AuNPs).[5,13,16,24,25] Several groups have reported physiological studies of particles
combining ICG and gold, but these particles have several key drawbacks. For example,
they incorporated significant quantities of inert binding materials (serum albumin, [26,27]
silica,[28–31] poly(styrene-alt-maleic anhydride),[32] polyethyleneimine,[32,33] chitosan[27,34],
and poly(lactic-co-glycolic acid[27]), thereby reducing the per-particle loading of
functionally active ICG and Au. Also, almost all of these studies used large gold
particles (15 - 150 nm), which are well-known to display protracted physiological
elimination.[35,36] We have previously demonstrated the utility of using 2-nm
dodecanethiol-coated AuNPs in micellar nanoformulations: they can be densely packed
to provide high Au payloads with extremely low non-gold mass, while their small
individual size facilitates long-term physiological clearance.[37,38] In the current study,
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ICG was successfully formulated at high concentrations into a stable nanoformulation
with ultrasmall hydrophobic AuNPs. These dual-component nanoclusters show
favorable long-term biological clearance, as well as great promise for both photoacoustic
imaging and photothermal therapy.
3.3 Results and Discussion
Preparation and Characterization of ICG-AuNP Clusters
ICG and gold were formulated into a stable, water-soluble nanomaterial using a
rapid and facile nanoemulsion methodology (Figure 3.1A). We first synthesized
ultrasmall hydrophobic gold nanoparticles (AuNPs) consisting of 2-nm gold cores coated
with dodecanethiol (Figure 3.2A,B).[39] Small clusters of AuNPs were then solubilized by
using ICG as an amphiphilic coating. To prepare these clusters, ICG was combined with
AuNPs in organic solvent and then emulsified into water, driving self-assembly of the two
materials into discrete spheroids (Figure 3.1B,C). TEM images confirmed the expected
clusters of ultrasmall AuNPs. ICG is not visible in such images, preventing observation
of ICG location; however, we consistently observed that clusters in close proximity
display a thick “halo” that could be indicative of ICG presence on the surface (Figure
3.1B, inset). Clusters exhibited a favorable hydrodynamic size and narrow size
distribution (61.22 ± 2.63 nm); this diameter stayed constant over time, suggesting that
clusters remain stable in water without detectable aggregation (Figure 3.1D). Due to the
inclusion of ICG, clusters were found to be highly negatively-charged, with a zeta
potential of –26.1 ± 12.6.
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Figure 3.1. (A) Schematic of ICG-AuNP clusters, consisting of 2-nm dodecanethiol-coated gold
nanoparticles (AuNP) packed within the core and coated with a dense outer layer of indocyanine green
(ICG). (B) TEM images of clusters. (C) DLS of clusters in water showing hydrodynamic diameter; the
average hydrodynamic diameter was 61.22 ± 2.63 nm (standard deviation, n = 2 particle batches). (D) Peak
hydrodynamic diameter of clusters in solution (water, 4°C, dark) over the course of one week. n = 3
measurements, ± SEM. (E) Absorbance (solid lines) and fluorescence (dashed lines) of clusters dissolved
in serum vs. equivalent concentrations of free ICG (3 µg mL-1 ICG) or dodecanethiol AuNPs (20 µg mL-1 Au).
Cluster absorbance maximum = 803 nm; fluorescence maximum = 820 nm.
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Figure 3.2. Dodecanethiol-coated gold nanoparticles (AuNPs). (A) Electron micrograph of AuNPs (scale
bar = 20 nm). (B) Size distribution of AuNPs, determined by measuring the diameter of 100 individual
particles. The average diameter was 2.42 ± 0.5 nm (standard deviation). (C) Electron micrograph of
polymer-AuNP clusters (scale bar = 50 nm). (D) Size distribution of polymer-AuNP clusters, measured by
dynamic light scattering (± standard deviation, n = 3 measurements).

We then sought to further understand the interaction between ICG and AuNPs
within the cluster, and assess whether ICG might displace dodecanethiol on the AuNP
surface. Knowing that ICG, but not dodecanethiol, is soluble in dimethylformamide, we
dissolved ICG-AuNP clusters in this medium and centrifuged to separate out any
insoluble material. The precipitate was found to be soluble only in highly nonpolar
solvents such as toluene and the absorbance spectra matched that of AuNPs, but not
ICG. In contrast, the absorbance spectra of the supernatant matched that of ICG, but
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not AuNPs. There was no mixing of spectral signals (Figure 3.3C). This suggests that
ICG is not covalently associated with the AuNP surface, and cluster assembly is likely
the result of noncovalent interactions such as hydrophobic self-assembly. We also
examined the clusters’ optical properties in aqueous solutions (Figure 3.1E; Figure
3.3A,B). Interestingly, the peak associated with clustered AuNPs demonstrated only a
very modest red-shift compared to the dispersed 2-nm AuNPs, despite the well-studied
impact of AuNP aggregation on surface plasmon resonance. [40] To confirm this effect,
we synthesized control AuNP clusters that are encapsulated with an amphiphilic
polymer, poly(ethylene glycol)-b-poly(ε-caprolactone) (PEG-PCL), instead of ICG.[37]
These polymer-AuNP clusters, which shared a similar size and structure as ICG-AuNP
clusters (Figure 3.2C,D), displayed an equivalent absorbance peak, suggesting this is a
shared feature of these nanostructures. When examining cluster absorbance peaks, we
also found that ICG demonstrated strong quenching when incorporated into this cluster
formulation, as observed by a reduction in fluorescence compared to equivalent
concentrations of free ICG. This likely results from a combination of mechanisms,
including self-quenching of ICG as a result of its tight packing on the surface of the
clusters, and quenching due to the close proximity of ICG to the AuNPs, as gold is
known to be an extremely effective quencher.[41,42]
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Figure 3.3. (A) and (B) Absorbance and fluorescence spectra, respectively, of ICG-AuNP clusters (3 µg mL1

ICG, 20 µg mL-1 Au) and equivalent concentrations of free ICG, dodecanethiol AuNPs, and polymer-AuNP

clusters. Separate spectra were collected in water, dimethylformamide (DMF), and toluene. (C) ICG-AuNP
clusters (3.4 µg mL-1, 23 µg mL-1 Au), dissolved in DMF and then centrifuged; the precipitate was then
dissolved in an equivalent volume of toluene.

In order to optimize cluster composition and yield, we synthesized a number of
different formulations of clusters by varying the relative amounts of ICG and AuNPs
(Figure 3.4; Table 3.1). As expected, increasing the concentration of AuNPs relative to
ICG resulted in more of the reagent ICG being successfully incorporated within clusters,
maxing out at approximately 70% ICG encapsulation efficiency. Within the columnpurified clusters, the ratio of ICG to Au was quite consistent across all nanoformulations
tested, with ICG mass approximately 5-10% compared to gold mass. We also observed
that using a larger initial ratio of AuNPs caused a moderate increase in cluster size,
despite the consistent proportions of ICG and Au. Ultimately, we determined that the
optimal cluster composition consisted of 2:16 ICG:AuNP (w/w) loading; this yielded
efficient incorporation of ICG relative to starting material, high loading of ICG relative to
Au, and favorable hydrodynamic diameter.
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Figure 3.4. Multiple cluster formulations were synthesized by varying the ratio of ICG to AuNPs. ICG
concentration was determined by absorbance, following dissolution in organic solvent; Au concentration was
determined by ICP-OES. Black marker indicates the formulation selected for all other experiments. (A)
Encapsulation efficiency of ICG into particles, which was calculated by dividing the ICG:Au ratios of the
reaction solutions after vs. before column purification (expressed as percentage). (B) Loading efficiency of
ICG within the purified particles, as calculated by the ICG concentration divided by Au concentration
(expressed as percentage). (C) Hydrodynamic diameter of the particles. n = 2 particle batches, ± SEM.

mg ICG:
mg AuNPs

Encapsulation
Efficiency (%)

ICG
Loading (%)

Hydrodynamic
Diameter

PDI a

2:4

9.24 ± 1.19

7.52 ± 1.78

37.42 ± 5.98

0.138

2:6

10.61 ± 0.36

5.56 ± 1.00

45.02 ± 0.04

0.116

2:8

19.92 ± 1.30

7.91 ± 1.00

49.31 ± 4.36

0.133

2:10

30.49 ± 14.16

7.74 ± 2.20

46.69 ± 5.54

0.138

2:12

35.53 ± 6.45

9.16 ± 1.21

54.81 ± 2.25

0.148

2:14

47.18 ± 18.11

8.09 ± 1.61

55.65 ± 5.09

0.144

2:16

67.83 ± 15.21

9.82 ± 0.28

61.22 ± 2.63

0.138

2:18

55.70 ± 4.08

8.41 ± 0.24

59.98 ± 2.33

0.124

2:20

70.19 ± 7.72

7.97 ± 0.44

68.92 ± 9.29

0.149

Table 3.1. Summary of Figure 2. Multiple cluster formulations were synthesized by varying the ratio of ICG
to AuNPs. Encapsulation efficiency of ICG was calculated by dividing the ICG:Au ratios of the reaction
solutions before vs. after column purification (expressed as percentage). ICG loading was calculated by the
ICG concentration divided by Au concentration (expressed as percentage). Hydrodynamic diameter is
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expressed in nanometers. Bolded text indicates the formulation selected for all subsequent experiments
(2:16). n = 2 particle batches, ± SEM.

In Vitro Imaging of ICG-AuNP Clusters
Aqueous solutions of clusters and free ICG were prepared in a range of
concentrations that were loaded simultaneously into imaging phantoms. We found that
clusters displayed intensity-dependent signal for both fluorescence imaging and
photoacoustic imaging (Figure 3.5). Notably, clusters demonstrated strong quenching
of fluorescence signal compared to free ICG; in contrast, photoacoustic signal intensity
was amplified in the nanoformulation, particularly at lower concentrations. These
complimentary phenomena can likely be explained by the tight packing of ICG and Au
within the cluster structure: close molecular proximity promotes collisional/selfquenching, decreasing the proportion of energy emitted radiatively (as fluorescence) and
increasing nonradiative emission (heat, read as ultrasonic emissions). [42–44] We also
collected photoacoustic spectra for polymer-AuNP clusters, knowing that many Au
nanoformulations generate photoacoustic signals. [5,13,16,24] These spectra suggest that
the polymer-AuNP cluster is only able to generate a modest photoacoustic signal
intensity within the NIR range, with decreasing intensity at longer wavelengths. This
corresponds with our data showing that ICG-AuNP clusters have similar PA spectra
compared to free ICG, with only a slight increase in signal due to the presence of the
AuNPs.
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ICG

Clusters

Figure 3.5. Phantom imaging of ICG-AuNP clusters in water vs. equivalent concentrations of free ICG and
polymer-AuNP clusters. (A) Fluorescence imaging (ex = 745, em = 820). (B) Quantification of fluorescence
signal intensity (radiant efficiency) as a function of ICG concentration. (C) Photoacoustic imaging (PA gain
30-40 dB, priority 95%, distance 12 mm from the transducer; transducer axial resolution, 75 µm; broadband
frequency, 13-24 MHz). (D) Complete PA spectra at varying concentrations. ICG-AuNP clusters and free
ICG are expressed as µg mL-1 ICG; polymer-AuNP clusters are shown at a gold dosage equivalent to that of
the 25 µg mL-1 ICG-Au clusters (167 µg mL-1 Au). (E) Quantification of PA signal intensity (810 nm) as a
function of concentration, compared to cluster concentration of ICG (shown) or Au (equivalent).

In Vitro Heating and ROS Generation of ICG-AuNP Clusters
Next, we examined the ability of clusters to generate heat upon irradiation.
Solutions of clusters in water and control solutions were treated with 808nm laser light
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(1.2 W power, 0.1 cm2 area), and temperature was recorded over time. Clusters were
found to generate significant temperature increases, higher than that of free ICG at
every concentration tested (Figure 3.6A). When solutions were irradiated in multiple
successive rounds, free ICG showed rapid degradation of its heating capacity, while
clusters showed repeated heating ability through multiple laser administrations (Figure
3.6C). Clusters were also dissolved in serum containing biologically-relevant
concentrations of hemoglobin, to compare their heating capacity relative to biological
chromophores (Figure 3.6B). Even at low cluster concentrations, clusters showed
significant and additive heating compared to hemoglobin alone, suggesting an
appropriate safety window could be attained in vivo.
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Figure 3.6. Solutions of ICG-AuNP clusters, free ICG, and various controls were prepared at room
temperature and then irradiated at 808nm (1.2 W power, 0.1 cm2 area) continuously for 10-30 minutes. (A)
Solutions in water; final solution temperature is plotted. (B) The temperature of water; fetal bovine serum;
clusters (0.0015 mg mL-1 ICG) in water; hemoglobin (155 mg mL-1) in fetal bovine serum; and clusters and
hemoglobin dissolved in serum at noted concentrations and heated for the indicated times. (C) Solutions in
water (0.015 mg mL-1 ICG), heated in multiple 10-minute increments and allowed to cool to room
temperature between successive rounds. (D) and (E) Clusters and free ICG (0.015 mg mL-1) were irradiated

89

in the presence of Singlet Oxygen Sensor Green, which detects formation of reactive oxygen species.
Controls included the following: samples containing sodium azide (10 mM), a known scavenger of singlet
oxygen; and non-irradiated samples heated to equivalent temperatures by external heat application.

ICG nanoformulations have been well studied both in photothermal therapy and
in photodynamic therapy, with many reports of dual activity for a single particle.[26,27,32,34]
To this end, ICG-AuNP clusters were also examined for their ability to produce reactive
oxygen species (ROS), which was monitored using the fluorescent reporter dye Singlet
Oxygen Sensor Green (SOSG) (Figure 3.6D,E). Irradiated clusters demonstrated a
strong time-dependent increase in SOSG signal. As observed in thermal studies,
clusters and free ICG showed similar activity during the initial moments of irradiation, but
free ICG appeared to exhaust its capacity more quickly. Further experiments confirmed
that the SOSG fluorescence signal was unchanged in the absence of irradiation, even
when equivalent levels of heat were applied directly to the solution. Moreover, we found
that the SOSG signal was strongly reduced in the presence of sodium azide (10 mM),
which is a known scavenger of singlet oxygen. Altogether, this provides strong evidence
that ICG-AuNP clusters can generate ROS and provide a combination of photodynamic
and photothermal therapy.
Cell Cytotoxicity of ICG-AuNP Clusters
After thorough physiochemical characterization of ICG-AuNP clusters in
nonbiological conditions, clusters were next examined for cytotoxicity in cell culture. For
these studies, we selected mouse 4T1 mammary carcinoma cells as a clinically relevant
model of highly-aggressive, triple negative breast cancer. [45] Cells were incubated with
increasing concentrations of clusters and free ICG, after which cellular viability was
quantified by MTT assay (Figure 3.7). No toxicity was observed under standard dark
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conditions, as evidenced by > 95% cell viability compared to media-only controls, even
up to the highest concentration tested (10 µg mL −1 ICG). However, in parallel
experiments, cluster treatment was combined with laser irradiation (0.2 W cm −2, 7
minutes); under these conditions, cytotoxicity dropped sharply at a cluster concentration
of 10 µg mL−1, resulting in nearly complete loss of cell viability (reduced to 5%).
Furthermore, this effect did not extend to free ICG, which showed only a moderate
decrease in viability (down to 69%). These results suggest that ICG-AuNP clusters
would be both well-tolerated systemically and highly effective at killing laser-targeted
tissues.

Figure 3.7. MTT assay of 4T1 cells incubated with ICG-AuNP clusters, free ICG, or standard media for 24
hours. A subset of cells was irradiated at 808 nm (0.2 W cm -2) for the first 7 minutes. n = 3 wells, ± SEM.
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In Vivo Biodistribution and Toxicity of ICG-AuNP Clusters
We next sought to understand how ICG-AuNP clusters would behave in vivo
under non-treatment conditions. First, we administered clusters to healthy mice (30 mg
kg−1 Au, 4.5 mg kg−1 ICG, I.V.) and measured gold content in the blood beginning at 5
minutes post-injection and lasting through the first 24 hours (Figure 3.8A). Clusters
showed an approximate blood half-life of 61 minutes; for comparison, non-nanoparticle
ICG has been previously reported to have a blood half-life of approximately 3 min.[46]

Figure 3.8. ICG-AuNP clusters (30 mg kg-1 Au, 4.5 mg kg-1 ICG, I.V.) were administered to naïve C57BL/6
mice and biodistribution was determined in key tissue compartments by ICP-OES analysis of gold. Results
expressed as percent injected dose per gram tissue. (A) Blood pharmacokinetics for the first 24 hours postinjection. (B) Tissue biodistribution for the first 28 days post-injection. n = 3 mice per timepoint, ± SEM;
urine and feces represent one sample each, pooled from three mice.

Next, we examined long-term biodistribution by measuring gold content in tissues
(Figure 3.8B). Clusters displayed a tissue biodistribution pattern that is typical for gold
nanoformulations, with high accumulation in the liver (34.8 ± 13 %ID g−1, day 1) and
spleen (25.6 ± 2.4 %ID g−1, day 1). Gold accumulation was low (< 3 %ID g−1) in all other
analyzed tissues, including brain, heart, kidney, and lung, and remained low over the
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course of the four-week study. Although elimination from the spleen remained
protracted, we found that the levels of gold in the liver decreased steadily, dropping over
3.5-fold over time. These results can likely be attributed to the particle design -specifically, that the incorporated gold comprises clusters of discrete ultrasmall AuNPs
rather than a large, solid core. Notably, during this time period, gold could be detected
in the feces, suggesting that elimination occurred through the hepatobiliary system.
Throughout this study, we examined several broad markers of toxicity. Animals
displayed no signs of illness, distress, or other behavioral alterations. Animal body
weight showed a small, insignificant decrease in the first several days, likely due to the
effects of injection and blood collection, but recovered fully over the course of four weeks
(Figure 3.9A). We also evaluated histology of key organs – liver, spleen, and kidney –
but found no evidence of pathology (Figure 3.9B).
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Figure 3.9. ICG-AuNP clusters (30 mg kg-1 Au, 4.5 mg kg-1 ICG, I.V.) were administered to naïve C57BL/6
mice. (A) Mouse body weights were recorded serially for three mice. Results expressed as ± SEM. (B)
Organ samples (liver, spleen, and kidney) were collected from mice at 1 day, 3 days, 7 days, and 14 days
post-injection; tissues were fixed in formaldehyde, embedded in paraffin, stained with H&E, and examined
for histology. Representative images from days 1 and 14 are shown.
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Finally, we assessed the short-term accumulation of clusters in murine orthotopic
tumors. For these and subsequent studies, 4T1 mammary tumors were implanted
orthotopically in immune-competent mice. When tumors surpassed 50 mm 3, mice were
injected with ICG-AuNP clusters (20 mg kg−1 ICG, 133 mg kg−1 Au, I.V.). Eighteen hours
later, we found 1.95 ± 0.4 %ID g−1 had accumulated in the tumor. This is consistent with
previously reported results for nanoparticle tumor accumulation. [47]
In vivo Imaging of ICG-AuNP Clusters
Having established in vivo tolerability of ICG-AuNP clusters, we next prepared to
evaluate their diagnostic and therapeutic potential in a mouse orthotopic breast cancer
model. We first sought to visualize tumors by photoacoustic imaging using accumulated
ICG-AuNP clusters as a contrast agent. Tumor-bearing mice were imaged both at
baseline and 18 hours after receiving either clusters or free ICG (20 mg kg −1 ICG, 133
mg kg−1 Au, I.V.) (Figure 3.10; Figure 3.11). Cluster-treated mice demonstrated high
signal intensity localized to the tumor; this signal was spectrally distinguishable from
background photoacoustic signal contributed by oxygenated and deoxygenated
hemoglobin. In contrast, mice who received free ICG showed very little overall signal.
These data correlate well with previous reports showing rapid clearance of ICG from the
body,[46] and emphasize that nanoformulations of ICG broaden its tissue imaging
applications.
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Figure 3.10. Photoacoustic imaging of 4T1 orthotopic mammary tumors in mice receiving either free ICG or
ICG-AuNP clusters (20 mg kg-1 ICG, 133 mg kg-1 Au, I.V.). (A) Representative images of mouse tumors at
18 hours post-injection. Left, ultrasound image; right, spectrally unmixed photoacoustic (color) image of
ICG/cluster distribution (yellow) as well as oxygenated (red) and deoxygenated (blue) hemoglobin signal.
(B) Quantification of PA signal intensity before injection and 18 hours after injection; left bars show total PA
intensity, right bars show intensity associated with spectrally unmixed ICG/cluster signal. n = 3 mice per
group, ± SEM.
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Figure 3.11. Photoacoustic imaging of 4T1 orthotopic mammary tumors in mice receiving either free ICG or
ICG-AuNP clusters (20 mg kg-1 ICG, 133 mg kg-1 Au, I.V.). Images were collected both prior to injection and
18 hours post-injection, with columns matched for individual mice. Within each box, ultrasound images (left;
gray) are displayed next to spectrally unmixed photoacoustic images (right; yellow = clusters/ICG, red =
oxyhemoglobin, blue = deoxyhemoglobin).
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In vivo Heating of ICG-AuNP Clusters
Finally, we evaluated antitumor efficacy in a photothermal therapy model. In
these studies, we delivered irradiation subcutaneously using a surgical model. Mice with
established 4T1 tumors (50 mm 3) were treated with either saline, free ICG, or ICG-AuNP
clusters (20 mg kg−1 ICG, I.V.); eighteen hours later, mammary tumors were exposed by
skin incision and directly irradiated for 30 minutes (0.7 W cm −2, 1.13 cm2 laser area).
During irradiation, we observed an increase in tumor temperature for all groups (Figure
3.12A,B). However, cluster-treated mice demonstrated the most profound heating
effect, ultimately rising approximately 13 °C above body temperature (13.4 ± 2.3 °C). In
contrast, tumor temperature rose only moderately in saline- and free ICG-treated
animals (6.4 ± 0.9 °C and 6.7 ± 0.8 °C, respectively). Indeed, free ICG appeared to
improve hyperthermia very modestly at early timepoints – though still less than ICGAuNP clusters – but the effect was not sustained; this observation coheres well with our
in vitro data showing a rapid plateau of heating capacity (Figure 3.6A,B).
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Figure 3.12. Mice bearing 4T1 orthotopic breast tumors were injected with saline, free ICG, or ICG-AuNP
clusters (20 mg kg-1 ICG, 133 mg kg-1 Au, I.V.); eighteen hours later, a subset of mice also received
subcutaneous laser irradiation (0.7 W cm-2, 1.13 cm2 laser area, 30 minutes). n = 5 mice per group, for a
total of six groups. (A) Representative thermographic image during treatment. (B) Quantification of thermal
imaging data over time, expressed as the difference between tumor temperature and animal body
temperatures (average temperatures in fixed-size regions of interest). (C) Tumor growth curves, averaged
among groups; day -1 = injection, day 0 = laser treatment or no treatment. (D) Kaplan-Meier curve
demonstrating animal survival. Data shown ± SEM; * = p < 0.05; n.s. = no statistical significance.

Mammalian cell death typically occurs at temperatures > 42-44 °C, though this
effect is contingent on duration of heating as well as other factors such as cell type. [48]
We observed that cluster-treated tumors surpassed 43 °C within 5 minutes of heating,
reaching an ultimate recorded temperature of 52.3 ± 2.3 °C by 30 minutes (Figure 3.13).
This was a marked improvement over both control groups, which required more than 10
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minutes to exceed 42 °C and which attained significantly lower final temperatures (free
ICG: 45.6 ± 1.4; saline: 43.6 ± 1.2 °C). It is important to note that tumor hyperthermia
was observed using an infrared thermographic camera, which detects surface
temperature of tissues but cannot fully characterize the thermal environment within the
tumor.

Figure 3.13. Quantification of thermal imaging data from mice bearing 4T1 orthotopic tumors, treated with
saline, free ICG, or ICG-AuNP clusters (20 mg kg-1 ICG, 133 mg kg-1 Au, I.V.), and then treated with
subcutaneous laser irradiation (0.7 W cm-2, 1.13 cm2 laser area, 30 minutes) eighteen hours later. Data
show the maximum temperature observed in the tumor for each group. n = 5 mice per group, for a total of
three groups, ± SEM.

We next tracked long-term tumor growth in these photothermally-treated mice, as
well as in control mice receiving drugs or saline alone (Figure 3.12C; Figure 3.14). We
observed statistically significant tumor shrinkage in mice that received the therapeutic
combination of ICG-AuNP clusters with laser irradiation. This response was robust:
average tumor size regressed below pre-treatment volume within two days of therapy,
continued to drop until Day 6, and remained below the initial volume for a total of 11
days. Only one other experimental group displayed regression – those receiving free
ICG and laser therapy together – but this decrease was brief (one day) and modest (did
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not reach pre-therapy size). ICG-mediated PTT was not significantly more effective than
controls at any time. In contrast, PTT with ICG-AuNP clusters showed significant
improvement over PTT with ICG (p < 0.05, day 6 onward) as well as PTT-alone,
clusters-alone, ICG-alone, or no treatment (p < 0.05, day 2 onward).

Figure 3.14. Individual tumor growth curves for all 4T1 tumor-bearing mice receiving injections of saline,
free ICG, or ICG-AuNP clusters (20 mg kg-1 ICG, 133 mg kg-1 Au, I.V.). A) Mice receiving drugs alone; day 1 = injection. B) Mice receiving drugs plus laser irradiation (0.7 W cm-2, 1.13 cm2 laser area, 30 minutes)
eighteen hours after injection; day 0 = laser treatment.

When comparing all treatment groups to the control (saline with no PTT), we
found a significant improvement in animal survival for mice receiving clusters and laser
irradiation (p = 0.032); no other group showed statistical significance (Figure 3.12D).
Notably, two out of five mice that received cluster-mediated PTT displayed complete
remission of the primary tumor (Figure 3.14B). One of these mice died on Day 22,
potentially of a tumor metastasis, which is common for this model[45] and which was
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supported by an observation of 15% body weight increase, suggesting ascites; however,
the other mouse survived until termination of the study on Day 60, indicating full disease
remission.
3.4 Conclusion
We set out to create a nanoformulation incorporating two common and wellcharacterized materials: indocyanine green, a clinically-approved dye, and gold
nanoparticles, which are also utilized in ongoing clinical trials. We found that these two
materials formed a stable nanocluster structure – despite the absence of additional
binding or solubilization reagents – and demonstrated excellent in vitro and in vivo
biological interactions, including low toxicity, effective tumor localization, and good
excretion over time. Knowing that both ICG and AuNPs are highly effective in
photoacoustic imaging and photothermal therapy, we set out to characterize ICG-AuNP
clusters in these modalities. Both in vitro and in vivo data indicated that the
nanoparticles are potent and specific imaging reagents, and are highly effective at heat
production. We found that mice treated with clusters and laser irradiation – but not those
with free ICG and laser – could exhibit severe tumor cytotoxicity in a triple-negative
orthotopic breast cancer model; this included 40% complete remission of the primary
tumor and 20% complete remission of disease. Altogether, these ICG-AuNP clusters
represent a promising new nanomaterial for cancer diagnosis and therapy.
3.5 Experimental Section
Materials: Indocyanine green, gold (III) chloride trihydrate, tetraoctylammonium
bromide, 1-dodecanethiol, sodium borohydride, Sepharose® CL-4B, and sodium azide
were purchased from Sigma-Aldrich (St. Louis, MO). Poly(ethylene glycol)-b-poly(εcaprolactone) (PEG4k-PCL3k) was purchased from Polymer Source (Quebec, Canada).
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Singlet Oxygen Sensor Green Reagent, fetal bovine serum (FBS), Trypsin-EDTA,
Dulbecco’s Modified Eagle Medium (DMEM), and penicillin-streptomycin solution were
purchased from Thermo Fisher Scientific (Gibco; Waltham, MA). MTT assay kit was
purchased from Roche Diagnostics GmbH (Mannheim, Germany).

Synthesis of 2-nm hydrophobic gold nanoparticles: Dodecanethiol-coated gold
nanoparticles were synthesized according to a protocol modified from Brust et al., [39] as
previously described.[37,38,49] A stock solution of gold (III) chloride trihydrate (1 g mL −1)
was centrifuged at 16,000 x g for 30 minutes to eliminate seeds, and 306 µL of the
purified solution was diluted into 30 mL water to yield a 30 mM solution. In parallel, a 50
mM solution of tetraoctylammonium bromide was prepared by dissolving 2.19 g in 80 mL
toluene. These two solutions were combined in an acid-washed flask and stirred
vigorously, and 201 µL of 1-dodecanethiol was added. Finally, a 400 mM solution of
sodium borohydride was also prepared by dissolving 0.378 g in 25 mL water. This
solution was slowly and continuously pipetted into the gold mixture over the course of 15
minutes, and the resultant mixture was allowed to stir for 3 hours. The organic phase
was collected and washed as follows: the toluene solution was first diluted in a 6.5-fold
excess (v/v) of 95% ethanol, kept at –20 °C overnight, centrifuged to collect the
precipitated nanoparticles, and resuspended in a minimal volume of toluene. After a
total of two such wash cycles, the nanoparticle solution was transferred into pre-weighed
microcentrifuge tubes and the solvent was removed using a centrifugal evaporator
(CentriVap, Labconco Corporation, Kansas City, MO).

Synthesis of ICG-AuNP clusters: Dodecanethiol-coated gold nanoparticles were
dissolved in toluene at a concentration of 40 mg mL−1 (based on dry particle mass).
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Meanwhile, a second solution was prepared containing indocyanine green (ICG)
dissolved in dimethylformamide (100 mg mL −1); 20 μL of the ICG solution was then
diluted into a mixture of dimethylformamide and toluene (30 μL and 60 μL, respectively).
The diluted ICG was then combined with the primary gold nanoparticle solution (400 μL
for most studies, or 50-500 μL for a subset of studies). The resulting mixture was
pipetted into a glass vial containing 4 mL of water, and the sample was sonicated until a
homogeneous colloid was observed. To remove organic solvents, the emulsion was
allowed to stand overnight to evaporate toluene, then dialyzed in pure water to remove
dimethylformamide. For studies requiring the precise determination of bound and
unbound ICG, nanoclusters were further purified by passing through a Sepharose® CL4B column (1.5 x 12 cm), collected as a dark brown band that was visually distinct from
green ICG; in all other experiments, including cell and animal functional studies, clusters
were not purified by column. Finally, clusters were concentrated using a centrifugal
evaporator, then centrifuged at 400 x g for 10 minutes to remove large aggregates, and
generally stored at a concentration of 3-4 mg mL−1 for a period of several weeks.

Synthesis of polymeric-AuNP clusters: As experimental controls, AuNP clusters were
encapsulated within a polymeric micelle, according to a protocol modified from Al Zaki et
al.[35] Briefly, dodecanethiol-coated gold nanoparticles were dissolved in toluene at a
concentration of 17.5 mg mL -1 (based on dry particle mass). 200 µL of this solution was
combined with 3.5 mg of poly(ethylene glycol)-b-poly(ε-caprolactone) (PEG4k-PCL3k) and
sonicated thoroughly to combine. The resulting solution was pipetted into a glass vial
containing 4 mL of water, and the sample was sonicated until a homogenous colloid was
observed. To remove organic solvents, the emulsion was allowed to stand overnight to
evaporate toluene. Clusters were centrifuged once at 400 x g for 10 minutes to remove
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large aggregates, and then the supernatant was centrifuged twice at 3100 x g for 30
minutes to sediment desired micelles.

Physiochemical characterization: Nanoparticles (including dodecanethiol-coated gold
nanoparticles, ICG-AuNP clusters, and polymeric-AuNP clusters) were characterized by
a variety of physiochemical techniques. Gold particles were visualized using transition
electron microscopy (Tecnai T12, FEI, Hillsboro, OR) to determine core diameter.
Hydrodynamic diameter and zeta potential of clusters were also examined using
dynamic and electrophoretic light scattering, respectively (Zetasizer Nano ZS, Malvern
Panalytical, Malvern, United Kingdom); all DLS data was expressed by particle number.
ICG-AuNP clusters, free ICG, and dodecanethiol-coated AuNPs were also dissolved in
water, dimethylformamide, fetal bovine serum, and/or toluene to capture their
absorbance spectra (Varian-Cary 100 Bio spectrophotometer, Agilent Technologies,
Santa Clara, CA) and fluorescence spectra (FluoroMax-3 spectrofluorimeter, Horiba
Jobin Yvon, Edison, NJ).
To determine the composition of ICG-AuNP clusters, each constituent was
examined as follows. ICG concentration was determined by dissolving clusters in
dimethylformamide (> 95% v/v) and comparing absorbance at ʎ = 792 nm with a
standard curve for ICG. Gold concentration was determined using inductively-coupled
plasma optical emission spectroscopy (ICP-OES; Spectro Genesis, Spectro Analytical
Instruments, Kieve, Germany). Briefly, aqueous solutions of clusters (20-200 µL) were
placed in round-bottomed glass tubes with polytetrafluoroethylene-coated caps. To this
was added up to 300 µL of aqua regia (e.g., 75 µL nitric acid plus 225 µL hydrochloric
acid), and tubes were capped and allowed to stand at room temperature for several
hours. Finally, solutions were diluted up to a standard volume and then
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spectrometrically analyzed. ICG and Au concentrations in purified clusters were then
analyzed using the following equations:

Encapsulation efficiency =

ICG loading =

(ICG mass ÷ Au mass) after column purification
(ICG mass ÷ Au mass) before column purification

ICG concentration after column purification
Au concentration after column purification

× 100

× 100

(1)

(2)

In vitro imaging: Varying concentrations of ICG-AuNP clusters, ICG, and/or polymerAuNP clusters were dissolved in water and then imaged using a phantom. In one study,
solutions (50 µl each) were added to a 384-well plate and then examined by
fluorescence imaging (IVIS Spectrum In Vivo System, Perkin Elmer, Waltham, MA).
IVIS parameters: excitation, 745 nm; emission, 820 nm; lamp level, high; exposure time,
0.5 seconds; binning, (M)8; f, 2.
In a separate study, solutions were placed into polyethylene tubing (0.5-mm
diameter) submerged in water at a depth of 1-2 cm, and were examined by
photoacoustic imaging (Vevo Lazr, VisualSonics, Toronto, Canada). The LZ250
transducer was utilized (axial resolution, 75 µm; broadband frequency, 13-24 MHz).
Images were acquired with the following settings: PA gain 30-40 dB, priority 95%, and
distance 12 mm from the transducer. ICG-AuNP clusters and free ICG were examined
within a single imaging session at 30 dB, allowing direct comparison of signal intensities.

In vitro heating: Solutions of ICG-AuNP clusters, along with various controls, were
treated with laser irradiation to induce heating. One milliliter of prepared solution was
added to a 2-mL microcentrifuge tube, and a fiber optic thermometer (Nomad, Qualitrol106

Neoptix, Fairport, NY) was inserted 4 mm below the liquid surface. Solutions were then
irradiated with an 808-nm laser (OEM Laser Systems, Midvale, UT) at 1.2 W power (0.1
cm2 area). Irradiation continued for a period of 10 minutes, during which temperature
was recorded every 10 seconds. In a subset of experiments, solutions were first
irradiated for 10 minutes as described, then freely allowed to cool to their original preirradiation temperature; immediately after reaching this threshold, irradiation was
repeated for two additional 10-minute cycles with cooling between. All experiments were
performed at room temperature and with ambient light.

In vitro ROS generation: ICG-AuNP clusters and various controls were examined for
their ability to generate reactive oxygen species, using the reporter reagent Singlet
Oxygen Sensor Green. SOSG-containing solutions (2.5 mL, 10 µM SOSG) were added
to a quartz cuvette and mixed continuously by magnetic stirrer for 30 minutes. Aliquots
(60 µL) were withdrawn at each of the following timepoints: 0, 1, 5, 10, 20, and 30
minutes. Samples were then diluted 20-fold in water, and fluorescence was read by
fluorimeter (ex = 488 nm; em = 523 nm) and normalized to the 0-minute reading.
Solutions of ICG-AuNP clusters and free ICG (0.015 mg mL-1) were tested with or
without sodium azide (10 mM). Samples were either kept in the dark or were irradiated
continuously for 30 minutes (808 nm; 1.2 W power, 0.1 cm2 area). Irradiated samples of
clusters and ICG also had surface temperature monitored using a FLIR ONE thermal
imaging camera (FLIR Systems, Wilsonville, OR); based on this data, a subset of
samples were heated with equivalent temperature and timing under dark conditions
(heat generated by Varian-Cary 100 Bio spectrophotometer, thermal accessory).
Sample conditions generating greater than 1.5-fold change in SOSG fluorescence were
performed in triplicate; all others were performed as single assays.
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Cell culture: Mouse 4T1 breast cancer cells (ATCC, Rockville, MD) were cultured in
DMEM supplemented with 10% heat-inactivated FBS and 1% penicillin-streptomycin
(100 U mL−1 penicillin, 100 µg mL−1 streptomycin). Cultures were maintained at 37°C in
a humidified incubator with 5% CO2.

Cell viability by MTT assay: To determine cytotoxicity of ICG-AuNP clusters, 4T1 mouse
breast cancer cells were seeded in 96-well plates (white with clear, flat bottom) at a
density of approximately 1.0 x 104 per well. Cells were allowed to incubate overnight,
and then media was carefully removed from individual wells and replaced with fresh
media containing nanoclusters or free ICG at various concentrations (n = 3 wells per
condition). Plates were then incubated for 24 hours. Finally, media was removed and
cells were washed with phosphate buffered saline, then given fresh media and subjected
to a standard MTT assay. Results were expressed as % Cell Viability by comparing to
the average absorbance value (λ = 590) of cells treated with media alone (n = 3 wells
per plate used).
Nanocluster cytotoxicity was also examined in combination with laser irradiation.
In these experiments, to ensure isolation of environmental conditions, cells were plated
with two empty wells between them. The following day, plates were removed from
incubators and placed on a 37°C warming surface to maintain temperature. Media was
exchanged for fresh 37°C media containing nanoclusters or free ICG at various
concentrations (n = 3 wells per condition). Immediately after addition, wells were
irradiated with an 808-nm laser (0.2 W cm−2; 1.13 cm2 area) for a total of 7 minutes (84 J
cm−2). Plates were returned to the incubator for 24 hours, after which they were washed
and analyzed by MTT as described. Results were expressed as % Cell Viability by
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comparing to the average absorbance value (λ = 590) of cells treated with standard
media under dark conditions (n = 3 wells per plate used).

Animal and tumor models: Female mice (C57BL/6 or BALB/c), aged approximately 6-10
weeks, were obtained from Charles River Laboratories (Wilmington, MA). All animal
studies were conducted with approval by the University of Pennsylvania Institutional
Animal Care and Use Committee, in accordance with AAALAC guidelines and
accreditation. Mice were fed standard chow ad libitum unless otherwise noted.
In a subset of studies, BALB/c mice were inoculated with 4T1 mouse breast
cancer cells (2 x 106 cells per mouse, 50-80 µL total volume) injected orthotopically into
the fourth abdominal mammary pad. At the time of tumor inoculation, abdominal hair
was removed by application of depilatory cream; all tumor-bearing mice were also
switched to a low-fluorescence diet (Teklad global 18% rodent diet 2918, Envigo,
Madison, WI) to avoid interference with subsequent imaging studies. Tumor size was
established by first measuring two axes (length and width) with digital calipers, and then
estimating tumor volume using the following equation:

Tumor volume =

Length × Width2

(3)

2

Biodistribution and toxicity in tissues: C57BL/6 mice were injected I.V. (retro-orbitally)
with clusters at a dose of 30 mg Au (approximately 4.5 mg ICG) per kg body weight (n =
15 mice total). Blood samples (3-20 µL each) were collected from the tail vein at the
following timepoints post-injection: 5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 6
hours, 12 hours, and 24 hours. These samples were collected from a total of three mice
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per timepoint, such that all mice received either one or two blood collections, and all
groups were randomized with regards to subsequent study arm assignment. Blood
samples were pipetted directly into round-bottomed glass tubes and stored at room
temperature. Finally, samples were processed and analyzed for gold content using ICPOES as previously described, using up to 1000 µL of aqua regia (e.g., 250 µL nitric acid
plus 750 µL hydrochloric acid). For normalization purposes, blood samples were
considered to be 1 µL = 1 mg. Half-life was determined by fitting a double exponential
decay curve to the data using MATLAB software (Mathworks, Natick, MA).
These same mice were sacrificed at the following timepoints post-injection (n = 3
per group): 1 day, 3 days, 7 days, 14 days, and 28 days. Urine and feces samples were
also collected at these timepoints from lightly-restrained mice, and were pooled from
multiple mice within each group. At sacrifice, mice were first anesthetized with
isoflurane (3%, 2 L min−1 O2; isoflurane precision vaporizer, VetEquip, Pleasanton, CA),
exsanguinated via cardiac puncture, then euthanized by cervical dislocation. The
following organs were then extracted (intact whole organs, unless otherwise noted):
brain, heart, kidneys, liver (approximately 290 mg of right medial lobe), lung, muscle
(gastrocnemius), skin (approximately 80 mg from femoral region with hair removed),
spleen. Tissues were rinsed in phosphate-buffered saline after extraction, frozen until
ready for analysis, and then examined for gold content using ICP-OES. Briefly, collected
tissues were weighed and then transferred into round-bottomed glass tubes with
polytetrafluoroethylene-coated caps. To this was added up to 1000 µL of aqua regia
(e.g., 250 µL nitric acid plus 750 µL hydrochloric acid). Tubes were lightly capped and
allowed to stand at room temperature overnight. Solutions were diluted up to a standard
volume, then passed through 0.2 µm filters to remove any indigestible material. Finally,
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samples were spectrometrically analyzed. For normalization purposes, urine samples
were considered to be 1 µL = 1 mg.
To monitor animal toxicity, three of these mice (those ultimately sacrificed at 28
days) had their body weights periodically recorded. Also, for mice sacrificed between 1
day and 2 weeks, small samples of harvested tissue were analyzed for histology. The
following organ samples were collected: kidney (n = 3 per timepoint), liver (n = 3 per
timepoint), and spleen (n = 2 per timepoint). Tissue was fixed in formalin for 24-48
hours. Samples were then embedded in paraffin, sectioned, and stained with H&E by
the Penn Center for Musculoskeletal Disorders Histology Core (P30-AR069619). Slides
were imaged using an EVOS FL Auto Imaging System (Life Technologies) at 20x
objective, and tissue was examined for markers of pathology including infiltrating
immune cells, abnormal and multiple nuclei, apoptotic or necrotic events, and disruption
of tissue architecture.
In a separate study, BALB/c mice were implanted with orthotopic mammary
tumors as described (n = 5 mice). When tumor size surpassed 50 cm 3, mice were
injected I.V. (via tail vein) with clusters at a dose of 20 mg ICG (approximately 133 mg
Au) per kg body weight. Eighteen hours after injection, tumor size was recorded again
and mice were sacrificed as described. Tumors were extracted intact, frozen until
further analysis, and finally examined for gold content using ICO-OES.

In vivo imaging: BALB/c mice were implanted with orthotopic mammary tumors as
described. When tumor size surpassed 50 cm 3, mice were anesthetized with isoflurane
(1.8 - 3%, 2 L min−1 O2) and imaged by photoacoustic imaging as described. On the
same day, mice were injected I.V. (via tail vein) with clusters at a dose of 20 mg ICG
(approximately 133 mg Au) per kg body weight; control mice were injected with an
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equivalent dose of free ICG (n = 3 mice per group, two groups). Eighteen hours after
injection, mice were imaged by photoacoustic imaging as described. Spectral unmixing
techniques were used to separate the contrast agent signals from background signals
(i.e., oxyhemoglobin and deoxyhemoglobin) based on their PA spectra.

In vivo heating: BALB/c mice were implanted with orthotopic mammary tumors as
described. When tumor size surpassed 50 cm 3, mice were injected I.V. (via tail vein)
with ICG-AuNP clusters at a dose of 20 mg ICG (approximately 133 mg Au) per kg body
weight. Control mice were injected with an equivalent dose of free ICG or with 0.9%
saline (n = 5 mice per group, three groups).
Eighteen hours after injection, mice were subjected to subcutaneous
photothermal therapy. Briefly, mice were given preoperative analgesia (0.1 mg kg −1
buprenorphine, S.Q.) and anesthetized with isoflurane (1.8 - 3%, 2 L min−1 O2); body
temperature was maintained thereafter using a recirculating water pad (Kent Scientific,
Torrington, CT). The abdominal skin was sterilized (povidone-iodine and 70% ethanol)
and a sterile drape was placed. Next, a curved incision was made medial to the tumor,
and hemostat clamps were used to draw back the skin and expose the underside of the
tumor. Tumors were irradiated at 808 nm for 30 minutes (0.7 W cm −2; 1.13 cm2 laser
area, which fully covered all tumors; 1260 J cm−2). After the completion of illumination,
skin was sutured with nylon and mice were hydrated with subcutaneous saline. For the
subsequent 72 hours, mice were monitored at least daily for wound condition and signs
of distress, and were given additional buprenorphine (0.1 mg kg −1) for the first 24 hours
and as needed.
Immediately before and during the described laser therapy, tumor and abdomen
surface temperature were monitored using a FLIR ONE thermal imaging camera (FLIR
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Systems, Wilsonville, OR) at the following timepoints: pre-treatment, 5 min, 10 min, 20
min, and 30 min. Infrared images were later analyzed for 1) maximum temperature in
the tumor, and 2) temperature averaged over each of two 1.3 cm 2 circular regions of
interest, one centered on the tumor and one on an area of the shaved abdomen at least
8 mm away (thus approximating overall animal body temperature).
In addition to three groups of laser-treated mice, an additional three groups of
mice (n = 5 mice per group) with size-matched tumors were injected with equivalent
doses of either ICG-AuNP clusters, free ICG, or saline. These mice received no
additional therapeutic interventions.
Tumor volume was monitored in all six groups and calculated as described,
beginning a minimum of five days after tumor cell implantation and continuing until
animal death. Criteria for animal sacrifice included any of the following: tumor length
surpassed 15 mm; ulceration of the skin surpassed 7.5 mm; or animal gait was
considerably impacted. Animals were also monitored for weight change and body
conditioning score, changes in eating and elimination patterns, as well as other markers
of health and behavior.

Statistical analysis: Tumor growth curves were analyzed by type II ANOVA and pairwise
comparisons of tumor growth slopes, calculated using TumGrowth open-access
software (https://github.com/kroemerlab),[50] as well as by t-test of daily tumor volume
means, calculated using Microsoft Excel (Microsoft Co, Redmont, WA, USA). For
survival analysis, log-rank test was performed using MedCalc Software (Medcalc,
Mariakerke, Belgium),[51] comparing all groups to saline.
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CHAPTER 4: SUMMARY DISCUSSION, FUTURE DIRECTIONS, AND CONCLUDING
REMARKS

4.1 Summary Discussion and Future Directions
Biodegradability of clustered gold particles
Gold is a highly popular material in preclinical research, possessing a long
history and a well-explored range of formulations and applications; however, this breadth
of study has not translated to clinical adoption of gold particles. While many potential
explanations exist (e.g., expense of material, concerns of toxicity), it is likely that
biodegradation – or the lack thereof – plays a major role. Still, many reports do not
include an exploration of their material’s long-term clearance capacity. In this thesis, we
have considered gold biodistribution to be an indispensable aspect of particle
characterization and design. We have formulated our gold nanomaterials using
ultrasmall gold particles, which have demonstrated capacity for breakdown within the
body and excretion through hepatobiliary and/or renal routes. Specifically, this work has
built on our group’s previous reported formulations. In these studies, small individual
nanoparticles are clustered together within a larger micellar construct. This has the
advantages of conferring long circulation (optimizing size, presenting an outer
hydrophilic PEG surface), as well as packing multifunctional materials together (gold with
iron oxide, iron oxide with dyes), while retaining a facile synthetic process with high
volumes of functional cargo (encapsulation of hydrophobic materials within micelles).
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This methodology therefore installs many favorable features of nanoparticles while still
working towards the goal of biodegradability.
In our previous nanoformulations using 2-nm gold particles and PEG-b-PCL, gold
showed far better breakdown than would be expected for large solid gold cores. We
then improved upon this by decreasing the size of gold particles to 0.9 nm. However, we
still observed a fraction of gold that persisted within tissues long-term. Notably, within
several tissues – particularly the liver – we detected that particles cleared steadily during
early timepoints, but reached a plateau later on. This is an important observation
because it demonstrates the overall utility of long-term biodistribution studies to fully
capture important interactions, and it also highlights a specific deficiency in our particles’
clearance abilities. Based on this observation, we embarked on the current study using
environmentally sensitive materials, which we believed would further improve gold
elimination. We also chose to pursue the study out to the three-month timepoint, and
once again, we noticed distinct long-term changes in degradation. Namely, in a
compartment that had not experienced any early decrease in gold (i.e., the spleen),
levels began to fall between one and three months after injection. This clearly
demonstrates the complexity of nano-bio interactions and the necessity of gathering this
extended data when time and materials allow.
During our study, we found that clearance of gold was quite high (86% in liver,
72% in spleen). In order to improve even further, several strategies could be employed.
Although rates of cellular internalization were not examined in detail, it is plausible that
slow cell uptake contributed to the long-term biopersistence of gold and its “escape” from
our pH-mediate clearance mechanism. Therefore, future studies with this particle could
include formulation changes that help target it into cellular lysosomes. Opsonization is
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known to increase uptake by phagocytic cells (though it is also likely to shorten blood
circulation times), so perhaps the use of a less-stealthy material than poly(ethylene
glycol) would produce improvements. Alternatively, because liver clearance was overall
faster and more extensive than spleen clearance, efforts could be made to shift this
biodistribution balance through changes like tuning particle surface chemistry as well as
size. Such manipulations could likely be performed easily due to the modular nature of
our polymer micelles; different amphiphilic coatings could be tested without changing the
AcetalDextran-AuNPs, which already appear to have highly efficient breakdown
capabilities.
Importantly, in our analysis of these particles, we did not examine any
therapeutic or imaging functions, nor did we look at biodistribution of particles into solid
tumors. We consider such an analysis to be highly important and do not necessarily
assume that these particles will be as functional as previous formulations, especially
considering their less-efficient loading of gold cargos. However, we are hopeful that this
material – or other materials inspired by these techniques – could show good therapeutic
potential.
Functional applications of clustered gold particles
One of the hallmarks and great advantages of nanomedicine is the ability to
combine multiple functional moieties within the same particle. This has been
demonstrated in countless published works describing nanoparticle formulations with
nearly every imaginable combination of diagnostic and treatment modalities. Such
constructs have many benefits, including precise control over relative dosages at target
locations and the ability to address complementary clinical goals without repeat
intervention. The classic example of this paradigm is a nanoparticle that can traffic into
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solid tumors and enable A) imaging of tumor location and morphology, and B)
destruction of cancer cells. With this pairing, tumor ablation (through surgery,
radiotherapy, etc.) can be pursued more precisely and safely; furthermore, treatment
effectiveness can often be predicted and confirmed.
In this work, we have reported a nanoformulation that combined two highly
common materials – gold particles and indocyanine green – and explored their efficacy
for photoacoustic imaging and photothermal/photodynamic therapy. Our studies did not
directly integrate these interventions, largely due to a lack of instrumentation capable of
employing photoacoustic imaging data for guidance of optical irradiation. Such
technology could plausibly emerge in the future as each technique is studied further and
adopted into mainstream clinical practice.
The present work joins a cohort of our group’s reported structures (cited
throughout) that interchange various functional materials, demonstrating the strong
modularity of our nanoparticle cluster formulations. Thus far, cores have been
assembled from gold nanoparticles, iron oxide nanoparticles, and iron oxide doped with
elements like zinc and manganese; metal particles have been surface-coated with
alkanes, sugars, and lipids, and their sizes have ranged from 0.9 to nearly 15
nanometers; and different particles have been encapsulated within the same structure.
Additionally, the outer coating has been formed from a variety of amphiphilic molecules,
including long block polymers (> 7000 Da) and small molecules (< 600 Da). Imaging
applications have included photoacoustic, CT, MR, and fluorescence/optical; therapeutic
applications have included photothermal, photodynamic, radiosensitization, and drug
delivery. In summary, varying materials can be combined into stable structures that
often require little revision of experimental protocols, giving easy access to a broad
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range of specific functional applications. Furthermore, due to the relative simplicity of
materials and syntheses, these particles may have advantages in clinical development
processes including lead-finding and larger-scale manufacturing. Further research by
our group will continue to explore a range of materials and applications compatible with
these structures, and well as their translatability to the clinic.
4.2 Concluding Remarks
Gold nanoformulations have enormous potential to fulfill unmet clinical needs in
oncology. Several ongoing clinical studies have shown great promise for gold’s
biocompatibility and efficacy in applications such as imaging, drug delivery, and
radiosensitization. However, continued research is required to answer fundamental
questions about gold nanoparticles’ pharmacokinetics, long-term safety, and efficacy for
emerging treatment technologies. We are hopeful that this work, and subsequent
studies building upon it, will help diversify and improve therapies available to patients.
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